



# Unrivalled diversity: the many roles and reactions of bacterial cytochromes P450 in secondary metabolism†

Anja Greule,<sup>ab</sup> Jeanette E. Stok,<sup>c</sup> James J. De Voss<sup>\*c</sup> and Max J. Cryle<sup>id \*abd</sup>

Cite this: *Nat. Prod. Rep.*, 2018, 35, 757

Covering: 2000 up to 2018

The cytochromes P450 (P450s) are a superfamily of heme-containing monooxygenases that perform diverse catalytic roles in many species, including bacteria. The P450 superfamily is widely known for the hydroxylation of unactivated C–H bonds, but the diversity of reactions that P450s can perform vastly exceeds this undoubtedly impressive chemical transformation. Within bacteria, P450s play important roles in many biosynthetic and biodegradative processes that span a wide range of secondary metabolite pathways and present diverse chemical transformations. In this review, we aim to provide an overview of the range of chemical transformations that P450 enzymes can catalyse within bacterial secondary metabolism, with the intention to provide an important resource to aid in understanding of the potential roles of P450 enzymes within newly identified bacterial biosynthetic pathways.

Received 13th December 2017

DOI: 10.1039/c7np00063d

rs.c.li/npr

- |  |  |
|--|--|
| <ol style="list-style-type: none"> <li>1. Introduction to P450s</li> <li>2. Chemistry of P450 enzymes</li> <li>3. Bacterial biosynthesis pathways involving P450s             <ol style="list-style-type: none"> <li>3.1 Terpene metabolism                 <ol style="list-style-type: none"> <li>3.1.1 Biodegradation of monoterpenes</li> <li>3.1.2 Biodegradation of higher terpenes</li> <li>3.1.3 Steroid biodegradation</li> <li>3.1.4 Diterpene biosynthesis</li> <li>3.1.5 Carotenoid biosynthesis</li> <li>3.1.6 Sesquiterpene biosynthesis</li> <li>3.1.7 Unusual, multistep biosynthetic transformations</li> </ol> </li> <li>3.2 Fatty acid metabolism</li> <li>3.3 Alkaloid biosynthesis pathways</li> <li>3.4 Shikimate biosynthesis pathways</li> <li>3.5 Polyketide (PKS) biosynthesis                 <ol style="list-style-type: none"> <li>3.5.1 Classic P450 transformations in PKS biosynthesis</li> <li>3.5.2 Complex transformations mediated by P450s in PKS biosynthesis</li> <li>3.5.3 Less common P450-catalysed transformations in PKS biosynthesis                     <ol style="list-style-type: none"> <li>3.5.3.1 Dehydrogenation – bacillaene biosynthesis</li> <li>3.5.3.2 Aromatic crosslinking – oxidative dimerisation of flaviolin</li> <li>3.5.3.3 Tetrahydrofuran ring formation – aureothin biosynthesis</li> <li>3.5.3.4 C–S bond formation – griseoviridin and thio-lactomycin biosynthesis</li> </ol> </li> <li>3.5.4 P450s that accept protein-bound substrates in PKS biosynthesis</li> <li>3.5.5 P450-mediated protein recruitment during PKS modification</li> </ol> </li> <li>3.6 Peptide biosynthesis pathways                 <ol style="list-style-type: none"> <li>3.6.1 Ribosomally synthesised and post-translationally modified peptide (RiPP) pathways</li> <li>3.6.2 Nonribosomal peptide synthesis (NRPS) pathways                     <ol style="list-style-type: none"> <li>3.6.2.1 NRPS-bound substrates</li> <li>3.6.2.2 Peptide modification</li> </ol> </li> <li>3.6.3 Diketopiperazine (DKP) biosynthesis                     <ol style="list-style-type: none"> <li>3.6.3.1 tRNA-dependent DKP biosynthesis pathways</li> <li>3.6.3.2 NRPS-dependent DKP biosynthesis pathways</li> </ol> </li> </ol> </li> </ol> </li> <li>4. Conclusions</li> <li>5. Conflicts of interest</li> <li>6. Acknowledgements</li> <li>7. References</li> </ol> | <ol style="list-style-type: none"> <li>3.5.2 Complex transformations mediated by P450s in PKS biosynthesis</li> <li>3.5.3 Less common P450-catalysed transformations in PKS biosynthesis             <ol style="list-style-type: none"> <li>3.5.3.1 Dehydrogenation – bacillaene biosynthesis</li> <li>3.5.3.2 Aromatic crosslinking – oxidative dimerisation of flaviolin</li> <li>3.5.3.3 Tetrahydrofuran ring formation – aureothin biosynthesis</li> <li>3.5.3.4 C–S bond formation – griseoviridin and thio-lactomycin biosynthesis</li> </ol> </li> <li>3.5.4 P450s that accept protein-bound substrates in PKS biosynthesis</li> <li>3.5.5 P450-mediated protein recruitment during PKS modification</li> <li>3.6 Peptide biosynthesis pathways             <ol style="list-style-type: none"> <li>3.6.1 Ribosomally synthesised and post-translationally modified peptide (RiPP) pathways</li> <li>3.6.2 Nonribosomal peptide synthesis (NRPS) pathways                 <ol style="list-style-type: none"> <li>3.6.2.1 NRPS-bound substrates</li> <li>3.6.2.2 Peptide modification</li> </ol> </li> <li>3.6.3 Diketopiperazine (DKP) biosynthesis                 <ol style="list-style-type: none"> <li>3.6.3.1 tRNA-dependent DKP biosynthesis pathways</li> <li>3.6.3.2 NRPS-dependent DKP biosynthesis pathways</li> </ol> </li> </ol> </li> <li>4. Conclusions</li> <li>5. Conflicts of interest</li> <li>6. Acknowledgements</li> <li>7. References</li> </ol> |
|--|--|

<sup>a</sup>The Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia. E-mail: max.cryle@monash.edu

<sup>b</sup>EMBL Australia, Monash University, Clayton, Victoria 3800, Australia

<sup>c</sup>School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane 4072, Australia. E-mail: j.devoss@uq.edu.au

<sup>d</sup>Department of Biomolecular Mechanisms, Max Planck Institute for Medical Research, Jahnstrasse 29, 69120 Heidelberg, Germany. E-mail: max.cryle@mpimf-heidelberg.mpg.de

† The authors would like to acknowledge the outstanding and inspirational contributions of Paul Ortiz de Montellano to the field of cytochrome P450 research and of Prof. Sir Alan R. Battersby (1925–2018) to the molecular understanding of biosynthesis over the course of their careers.



# 1. Introduction to P450s

The cytochromes P450 (P450s) are a superfamily of heme-containing monooxygenases that play diverse catalytic roles in nature, both in terms of the substrates that they accept and the array of reactions that they catalyse.<sup>1</sup> P450 enzymes are easily identified by bioinformatic, structural or spectroscopic approaches due to the remarkable conservation of structure and catalytic mechanism that is found across the P450 superfamily, in spite of the low sequence identity that can exist between P450s.<sup>2,3</sup> In order to attempt the classification of P450s based on sequence conservation, the concept of families and subfamilies within P450s has been implemented, which leads to the official CYP nomenclature (families and subfamilies must share 40% and 55% sequence identity respectively).<sup>4</sup> Whilst relatively successful in higher eukaryotes, this approach has limited utility in bacterial systems, where substrate selectivity and

catalytic function can vary widely within P450 families – classic examples of P450 families that encompass members displaying highly diverse functions include the CYP105, CYP107 and CYP109 families.<sup>2,3,5,6</sup> Thus, care must be taken in assigning P450 functions in bacteria based purely on sequence conservation data, unless the level of conservation is very high (>55–65%).<sup>2,3</sup> Bacterial P450s are almost exclusively cytosolic proteins, which is a further significant difference to P450s in eukaryotic systems; none the less, bacterial P450s with high pI values can still associate with membranes even if there is no specific membrane anchoring element.<sup>7</sup> The structure of P450s is remarkably conserved, containing mostly  $\alpha$ -helical secondary structure (standard helices are labelled A–L) supplemented by one  $\beta$ -sheet region (Fig. 1).<sup>7</sup> The core of a P450 is formed by a four-helix bundle comprising the D, E, I and L-helices, with the prosthetic heme moiety at the centre of the P450 active site sandwiched between the I- and L-helices.<sup>7</sup> The I-helix, which runs across the top face of the heme moiety contains the



*AG studied Biology with focus on Microbiology/Biotechnology at the University of Tübingen and obtained her Ph.D. degree in Pharmaceutical Biology and Biotechnology from the University of Freiburg, Germany in 2016. Her doctoral research investigated the studies of different Actinomycetes strains for their ability to produce various secondary metabolites. Since January 2017, she has*

*been working as a postdoctoral fellow in the Cryle group, where her interests lie in P450 monooxygenases and other enzymes involved in the biosynthesis of the glycopeptide antibiotics.*



*JDV received a B.Sc (Hons) from the University of Queensland and undertook his Ph.D. on Vitamin B<sub>12</sub> as a Royal Commission for the Exhibition of 1851 scholar at Cambridge under the supervision of Prof. Sir Alan R. Battersby. After working at Johns Hopkins on the DNA cleaving enediyne calicheamicin he was introduced to the cytochromes P450 by Paul Ortiz de Montellano at UCSF. Since*

*returning to the University of Queensland, where he is now a Professor, he has continued his interest in the interface of chemistry and biology and currently works on P450 mechanism and the phytochemistry of herbal medicines.*



*JES completed her Ph.D. under the supervision of James De Voss at the University of Queensland. She then had the pleasure of working with carboxylesterases and epoxide hydrolases with Prof. Bruce Hammock at the University of California, Davis; and isopenicillin N synthase with Prof. Sir Jack Baldwin at the University of Oxford. Since then she has returned to the De Voss laboratory to work with*


*cytochromes P450 from a variety of organisms, including bacteria and plants.*



*MJC obtained his Ph.D. in chemistry from the University of Queensland in 2006. He then moved to the Max Planck Institute for Medical Research in Heidelberg Germany as an HFSP Cross-Disciplinary Fellow and later as an Emmy Noether group leader funded by the DFG. Since 2016 he is an EMBL Australia group leader based within the Biomedicine Discovery Institute at Monash University, where his*

*team focusses on understanding antibiotic biosynthesis (with particular interest in non-ribosomal peptide synthesis) as well as developing new antibiotics. Since 2018 he is funded as a Career Development Fellow by the National Health and Medical Research Council.*






**Fig. 1** Typical structure of a cytochrome P450, exemplified by OxyB<sub>tei</sub> (CYP165B7) from teicoplanin biosynthesis showing the preponderance of  $\alpha$ -helices in the structure (labelled A–L) together with one  $\beta$ -sheet ( $\beta$ -1/2). The core 4 helix bundle of the P450 is shown in deep red, with the exception of the I-helix that is shown in turquoise. The regions comprising the active site are shown in colours (BC loop region in pink, F-helix shown in orange, the G-helix shown in gold, the I-helix shown in turquoise, the  $\beta$ -strand following the K-helix shown in green and the C-terminal loop shown in black). The central heme moiety is shown as sticks.

typically conserved acid/alcohol pair usually important for the P450 active cycle (*vide infra*),<sup>7</sup> whilst the loop just prior to the start of the L-helix contains the cysteine residue that provides the crucial proximal axial thiolate ligand for the heme iron of the P450.<sup>7</sup> The proximal face of a P450 is also the site where interactions with redox partner proteins occur, with these processes largely appearing to be driven by electrostatic interactions.<sup>8</sup> The active site of P450s comprises regions that surround the distal face of the heme moiety, and include the so-called BC loop region between the B- and C-helices, the C-terminal region of the F-helix, the N-terminal portion of the G-helix, the centre of the I-helix, the  $\beta$ -strand following the K-helix and the C-terminal loop that impinges of the P450 active site (such regions are also referred to as substrate recognition sites, SRSs 1–6).<sup>9</sup> Variability within these regions leads to the ability of P450s to accept a wide range of different substrates (even those that are protein bound), whilst the retention of the general structure surrounding the active site heme group and axial cysteine ligand support the remarkable consistency of the P450 catalytic mechanism.<sup>7,10,11</sup>

## 2. Chemistry of P450 enzymes

Whilst xenobiotic metabolism in higher eukaryotes highlights the remarkable ability that P450s can exhibit for substrate plasticity, it is in the realm of bacterial P450s – particularly biosynthetic ones – where the truly remarkable range of chemical transformations that P450s are able to mediate is revealed. Furthermore, this is coupled with a remarkable range of different, complex substrates that highlights the amazing potential of these potent biocatalysts. Whilst the archetypal

P450-catalysed transformation, hydroxylation of unactivated C–H bonds remains the trademark P450-catalysed reaction, the reported range of chemical reactions able to be performed by P450s is ever increasing, and many examples of these are found in bacterial biosynthetic pathways: such reactions range from aromatic hydroxylation, alkene epoxidation and heteroatom oxidation to processes such as aromatic coupling and multi-step transformations.<sup>12,13</sup> One of the most impressive properties of P450s is that these reactions are all performed within a conserved active cycle (Fig. 2).<sup>7,14</sup> In this process, a carefully choreographed delivery of two electrons and two protons to molecular oxygen is performed by the P450, whilst the oxidative power of a P450 stems from a highly reactive intermediate generated, known as compound I (Cpd I).<sup>15</sup> This highly electrophilic oxidant, which has been identified as an iron(IV) porphyrin cation radical, is responsible for the vast majority of the oxidation chemistry displayed by P450s. The oxidative power of the compound I intermediate relies on a thiolate ligand for the heme iron in the P450 active site, which in turn requires P450s to be able to maintain this deprotonated thiolate group in spite of the elevated  $pK_a$  of this moiety.<sup>7</sup> In order to generate compound I, the P450 catalytic cycle begins with the displacement of the resting water (or hydroxide ion) from the heme iron upon substrate binding in the active site. The first electron is then transferred from a redox partner protein – typically a ferredoxin – that reduces the iron to  $Fe^{2+}$ . If this species is exposed to carbon monoxide, the resultant complex that forms provides a spectrum with a characteristic Soret maximum at 450 nm, for which P450s are named. In the typical active cycle, dioxygen binds to the reduced P450, which then triggers the delivery of a second electron to generate a species equivalent to ferric peroxy anion – a species that has been invoked as the active oxidant in some specific P450-mediated transformations.<sup>16</sup> The requirement of the P450-catalytic cycle for electrons is unusual for an oxidative enzyme, with these



**Fig. 2** Simplified representation of a generic P450 active cycle resulting in substrate hydroxylation.



electrons typically being derived from NAD(P)H *via* redox partner proteins. Next, the P450 controls the sequential delivery of two protons to the ferric peroxo species, specifically ensuring the protonation of the distal oxygen, through a hydrogen bonded water network established in part through the important acid/alcohol pair of residues typically found in the I-helix above the heme iron.<sup>7</sup> This initially leads to the formation of the ferric hydroperoxy intermediate known as compound 0, with the correct delivery of the second proton triggering scission of the O–O bond with concomitant the loss of water and generation of the highly reactive intermediate compound I.<sup>14</sup> Instances where protonation of the proximal oxygen occurs during the P450 active cycle lead to the formation of hydrogen peroxide in a process known as uncoupling. This process, whilst largely seen as deleterious, does present the opportunity for some P450s to reverse this process and to utilise hydrogen peroxide directly to bypass the early stages of the P450 active cycle and the necessity for exogenous electron donors. Known as the shunt pathway, this process has been identified as proceeding in several bacterial P450s, although these systems are in the minority compared to those enzymes that utilise a “traditional” P450 active cycle. In the archetypal P450 reaction – C–H hydroxylation – the reaction then proceeds with the abstraction of a hydrogen atom from the substrate, with production of a transient iron-(IV) hydroxyl intermediate known as compound II (Cpd II).<sup>17</sup> Rebound of this intermediate onto the substrate radical then affords the hydroxylated product and returns the enzyme to the resting state Fe<sup>3+</sup> state. Density function theory calculations suggest that the process of rebound can either proceed with or without a discrete intermediate depending upon the spin state of the intermediates, based upon what is known as two-state reactivity.<sup>10,11</sup> Substrate dissociation from the active site and water binding to the heme iron then complete the active cycle – which is one of the more impressive enzyme mechanisms given its complexity and ability to perform such unique oxidative chemistry.

### 3. Bacterial biosynthesis pathways involving P450s

The occurrence of P450s in bacteria is highly variable. Whilst the genome of the model organism *E. coli* has no identified P450 gene, many secondary metabolite producers like actinomycetes contain multiple P450 homologues. For example, *Streptomyces avermitilis* putatively contains 33 P450 encoding genes in its genome.<sup>18,19</sup> Recently, a comprehensive overview of the sequences, structures and functions of cytochrome P450 enzymes in *Streptomyces* strains has been published,<sup>6</sup> in which the number of homologues stands in contrast to the much lower number of P450s seen, for example, in *Bacillus subtilis*.<sup>20</sup> Bacteria can produce a great range of different secondary metabolites, which provide their bacterial producer strains a selective advantage under specific circumstances. Many of these metabolites have been exploited for use in human therapy for example as antibiotics, immunosuppressants or anticancer agents, which makes understanding their biosynthesis of great

importance. In bacteria, cytochrome P450 enzymes catalyse a broad range of physiologically important oxidative reactions with a high degree of chemo-, regio- and stereoselectivity, which are essential for the activity of the final pharmacologically active molecule. P450s are often associated with the major secondary metabolite pathways found in bacteria: polyketide synthesis (performed by polyketide synthases, PKSs); non-ribosomal peptide synthesis (performed by non-ribosomal peptide synthetases, NRPSs); ribosomally synthesised and post-translationally modified peptides (RiPPs); and traditional pathways that produce alkaloids, terpenes, steroids and fatty acids. The genes for the biosynthesis of such bacterial secondary metabolites are often located next to each other on the chromosome, and thus sequences encoding P450 enzymes are typically located within the respective secondary metabolite gene cluster. In some cases, P450s are co-transcribed with their immediate redox partner, typically an Fe-containing ferredoxin, although this is not always the case and many instances have been reported where (multiple) bacterial P450s can accept electrons from a range of endogenous redox partners within the parent bacterial strain.<sup>21–24</sup> Even though many P450s identified in bacteria can be assigned to a specific biosynthetic cluster, this does not always make the identification of their biosynthetic role a facile process. One representative example of such a scenario is seen in clavulanic acid biosynthesis, where P450<sub>cla</sub> (Orf10) has been identified as a part of the gene cluster for more than 15 years.<sup>25</sup> In spite of the identification of this P450 within the clavulanic acid biosynthetic cluster, the presence of a presumed ferredoxin redox partner and knockout studies showing the importance of this enzyme in clavulanic acid biosynthesis, no definitive study demonstrating the substrate or catalytic mechanism of this P450 has yet been published. Whilst the likely role of P450<sub>cla</sub> is the oxidative deamination of clavaminic acid, the exact mechanism of this reaction which affords clavulanate-9-aldehyde *via* “oxidative enantiomerisation” remains unknown (Fig. 3).<sup>25</sup> This serves as a salient reminder that assigning the presumed activity of a P450 enzyme within a biosynthetic pathway can remain challenging.

#### 3.1 Terpene metabolism

Terpene oxidation mediated by P450s provides the perfect platform from which to appreciate the power and complexity of the chemistry mediated by these enzymes. It ranges from the simple in concept but energetically impressive insertion of oxygen into an unactivated C–H bond through to multistep,



Fig. 3 Postulated function of P450<sub>cla</sub> within clavulanic acid biosynthesis, with the oxidative deamination reaction also proceeding with inversion of stereochemistry of the hemiaminal ether centre of clavaminic acid. The oxygen incorporated as a result of this process is indicated in red.



intermediate laden transformations that dramatically alter molecular structure and function. P450s have been reported that catalyse the oxidation of terpenes ranging from the relatively simple C<sub>10</sub> monoterpenes to the much larger C<sub>40</sub> carotenoids in mesophilic and thermophilic bacteria. These oxidation reactions are sometimes associated with the formation of a stable secondary metabolite or the degradation of one to alter its function or provide an energy source for the bacterium. This section will cover the modification of terpenes where this is believed to be the primary, natural function of the P450 in either biosynthesis or biodegradation as the chemistry of these pathways is the same even if the biological context differs.

**3.1.1 Biodegradation of monoterpenes.** For historical reasons, simple monoterpene hydroxylation is perhaps the most widely reported and studied bacterial P450 catalysed transformation. Such a transformation is usually employed to provide a functional group that allows biodegradation of monoterpenes. This in turn allows the organism to access the high levels of energy sequestered in these reduced hydrocarbons and live on them as their sole source of carbon and energy, thus providing a ready selection process for the isolation of the P450 producing organism. As monoterpenes are widespread in the environment – Australian eucalypt forests are estimated to produce 500 000 tons of cineole alone per year<sup>26</sup> – the ability to utilise them as a carbon source is similarly common. The archetypal and best studied P450, P450<sub>cam</sub> (CYP101A1) from *Pseudomonas putida* was isolated utilising this strategy and catalyses the hydroxylation of (1*R*)-camphor to (1*R*)-5-*exo*-hydroxycamphor as the first step in its biodegradation.<sup>27</sup> P450<sub>lin</sub> (CYP111A1),<sup>28,29</sup> P450<sub>terp</sub> (CYP108A1)<sup>29</sup> and P450<sub>cin</sub> (CYP176A1)<sup>30</sup> were similarly isolated and characterised in organisms that lived on: linalool (*Pseudomonas incognita* now *Acinetobacter baylyi* strain ATCC 33305/BD413/ADP1); terpineol (*Pseudomonas* sp.); or cineole (reported to be *Citrobacter braakii* but now believed to be a *Rhodococcus* sp.). P450<sub>cam</sub> and P450<sub>cin</sub> catalyse the enantiospecific hydroxylation of a methylene whilst P450<sub>lin</sub> and P450<sub>terp</sub><sup>31</sup> mediated the regiospecific hydroxylation of an allylic methyl group (Fig. 4). In all cases, this oxidation is the first step in an oxidative cascade of reactions that permit conversion of the terpene into fatty acid like molecules that can be taken up into primary cell metabolism with concomitant production of NAD(P)H. Together, these enzymes have had a profound impact on the way P450 chemistry is understood,

providing accessible model systems for mechanistic studies and a multitude of X-ray crystal structures<sup>32–34</sup> that provided insight into substrate binding and mechanism of oxidation. Interestingly, they were all found to be closely associated with their required redox partners in the bacterial genome, a situation that has not occurred for most subsequently identified bacterial P450s. The redox partners for P450<sub>cam</sub> (the ferredoxin putidaredoxin and the NADH dependent putidaredoxin reductase) defined class I electron transport in P450s whilst the flavodoxin dependent P450<sub>cin</sub> defined class III enzymes.<sup>35</sup> A number of other monoterpene degrading P450s have subsequently been identified by genome mining and characterised. These include: CYP101D2, a camphor metabolising P450 that also produces (1*R*)-5-*exo*-hydroxycamphor;<sup>36</sup> CYP111A2 which oxidises linalool in the same way as P450<sub>lin</sub>;<sup>36</sup> CYP101J2, J3 and J4 which oxidise cineole to a stereoisomer of the one produced by P450<sub>cin</sub>.<sup>37,38</sup> Interestingly, none of these enzymes was found closely associated with native redox partners. In the case of CYP102D2 and CYP111A2, a ferredoxin/ferredoxin reductase pair that supported P450 activity was found encoded elsewhere in the genome of the organism (*Novosphingobium aromaticivorans*) that produces both of these P450s.<sup>36</sup> This shared use of redox partners is the strategy commonly found for biosynthetic P450s (*vide infra*). P450<sub>camR</sub> from *Rhodococcus* sp. NCIMB 9784, for which no DNA sequence information appears available, hydroxylates (1*R*)-camphor to 6-*endo*-hydroxycamphor.<sup>39</sup> This in turn implies that, as P450<sub>camR</sub> and P450<sub>cam</sub> produce structurally isomeric products, biodegradation must proceed by different pathways, unlike the different linalool and cineole oxidising P450s which produce the same or stereoisomeric products. Finally, it is worth noting that not all monoterpene biodegradation relies upon P450s. *p*-Cymene biodegradation begins with monohydroxylation of the benzylic methyl group but to date in the pathways discovered this is mediated by a non-heme iron oxygenase.<sup>40</sup>

**3.1.2 Biodegradation of higher terpenes.** The biodegradative pathways, and hence the role of P450s in these pathways, of higher terpenes (sesqui-, di-, sester- and tri-terpenes) are in general much less well understood. Members of the CYP226A family are known to be involved in the early stages of metabolism of the tricyclic abietane diterpenoids and CYP226A1 has been shown to hydroxylate dehydroabietic acid at C7 in a key early step in their utilisation as carbon sources




Fig. 4 Important examples of bacterial P450-mediated hydroxylation of monoterpenes, leading to the eventual biodegradation of these compounds. P450 generated hydroxyl groups are indicated in red.






Fig. 5 Diterpene and steroid oxidation in bacterial P450 catalysed biodegradation. Examples shown for a diterpene is abietic acid (A) and for steroids cholesterol (B) and lanosterol (C).

(Fig. 5A).<sup>41,42</sup> The chemical necessity for C7 oxidation or for its placement early in the pathway are unclear. Orthologous CYP226A encoding genes are found in a variety of bacteria that are known to degrade abietic acid derivatives, with minor differences in exact substrate specificity and function proposed.<sup>42</sup> In the operons encoding this pathway, the P450s are generally found associated with ferredoxin/ferredoxin reductase genes and in the case of CYP226A1 a co-encoded ferredoxin has been shown to support *in vitro* activity.<sup>43</sup>

**3.1.3 Steroid biodegradation.** Utilisation of cholesterol by *Rhodococcus* sp. and *Mycobacterium* sp. has been investigated, in part because it has recently been shown that inhibition of this pathway may provide a novel therapeutic strategy against *Mycobacterium tuberculosis*.<sup>44</sup> As with monoterpene utilisation, this complex pathway is initiated by P450 mediated hydroxylation. Members of the CYP124, CYP125 and CYP142 families have been shown to stereospecifically hydroxylate the stereochemically different terminal methyl groups of the steroid sidechain, enabling subsequent biodegradation by a  $\beta$ -oxidation pathway (Fig. 5B).<sup>45</sup> (CYP124 has also been shown to be hydroxylate the terminal methyl of iso-branched fatty acids (*vide infra*)). A ferredoxin is found included in the over 50 genes associated with this pathway, but the role of this enzyme as a possible P450 redox partner is unknown. As will be seen with a number of biosynthetic P450s, these enzymes are multifunctional. In this case, they consecutively oxidise the same methyl group three times, converting it *via* alcohol and aldehyde intermediates into a carboxylic acid, which allows ligation of coenzyme A and subsequent  $\beta$ -oxidation. Another P450, CYP51, involved in steroid metabolism has also been found in several bacterial species: *M. tuberculosis*;<sup>46,47</sup> *M. smegmatis*;<sup>48</sup> *M. avium*;<sup>49</sup> *Rhodococcus triatomae*;<sup>50</sup> and *Methylococcus capsulatus*.<sup>51</sup> This family of P450s is widespread and found in bacteria, plants and animals and is responsible for the removal of the 14- $\alpha$ -methyl group from related intermediates in the sterol biosynthetic pathway (Fig. 5C). This multistep reaction two involves sequential hydroxylations of an angular methyl group resulting in the formation of a formyl intermediate. This is believed to react with the ferric peroxo form of the P450 and the resultant intermediate undergoes loss of formic acid with concomitant

alkene formation.<sup>27</sup> Given that the bacteria found to encode CYP51 do not all contain sterol biosynthetic pathways but many are associated with sterol utilisation as a carbon and energy source, the function of CYP51 in these organisms may be biodegradative rather than biosynthetic. A number of these bacterial CYP51s are found encoded along with ferredoxins and in fact the enzyme from *M. capsulatus* is a novel fusion between a P450 and a putative 3Fe-4S ferredoxin.<sup>51</sup>

**3.1.4 Diterpene biosynthesis.** In contrast to biodegradative transformations, the biosynthetic functions of cytochrome P450s have been better recognised in the formation of higher terpenes. Once again, these may take the form of simple hydroxylation reactions (Fig. 6) or multistep complex transformations. Simple hydroxylation is seen in the formation of the diterpene glycoside antibiotic phenalinolactones where at least three different P450s oxidise a methylene (P450 PlaO5) or diastereotopic methyl (PlaO4 and PlaO3) groups.<sup>52–54</sup> In the case of the methyl groups, these pendant hydroxyls provide points of attachment for acyl or glycosyl moieties (*cf.* polyketides *vide infra*) and result in the P450s acting on structurally quite distinct substrates. Interestingly, as with many biosynthetic monooxygenases, the operon encodes no obvious redox partners for these P450s but does contain another P450 of so far unknown function.<sup>52–54</sup> Similarly, CYP1051A1 is encoded in a diterpene biosynthetic operon in the marine organism *Salinispora arenicola* without any redox partner and is responsible for diastereoselective methyl hydroxylation.<sup>54</sup> The cyclooctatin gene cluster in *Streptomyces melanosporofaciens* is responsible for the biosynthesis of the unusual eponymous diterpene, the skeleton of which is formed *via* an unusually complex and cryptic rearrangement pathway.<sup>55</sup> The two encoded P450s CotB3 and CotB4 catalyse simple, regio- and stereospecific methylene and methyl hydroxylations.<sup>56</sup> Although again, the operon contains no redox partners for the P450s, it has been shown that heterologous co-expression of a reductase/ferredoxin system from *Streptomyces afghaniensis* led to more efficient *in vitro* oxidation than the putidaredoxin/reductase system.<sup>57</sup> These results are consistent with a common reductase/ferredoxin system coupling to a number of P450s in *Streptomyces*.

**3.1.5 Carotenoid biosynthesis.** Carotenoid hydroxylation in several bacteria has been attributed to P450s (Fig. 7). CYP175A1 has been shown to be a carotene hydroxylase from the thermophilic organism *Thermus thermophilus* HB27.<sup>58</sup> It is responsible for simple hydroxylation, albeit of this very large hydrophobic molecule and it actually hydroxylates two symmetry related methylenes at either end of the carotene skeleton. Although thermophilic, it has been reconstituted *in vitro* with the mesophilic putidaredoxin/reductase system.<sup>59</sup> CYP287A1 is from a radiation resistant bacterium *Deinococcus radiodurans* and is a C2 methylene hydroxylase of the monocyclic carotenoid, deinoxanthin.<sup>60</sup>

**3.1.6 Sesquiterpene biosynthesis.** The P450s associated with sesquiterpene biosynthesis seem to be associated with unusual activities apart from oxidation. In the biosynthesis of the tricyclic antibiotic albaflavenone, CYP170A1/2 catalyses the sequential oxidation of an allylic methylene to a ketone *via* an alcohol intermediate (Fig. 8A).<sup>61</sup> Unusually, the initial






Fig. 6 Biosynthetic roles of bacterial P450s in diterpene biosynthesis. Hydroxyl groups generated by P450 action are indicated in red.




Fig. 7 Biosynthetic roles of bacterial P450s in carotenoid biosynthesis.

hydroxylation is not stereospecific giving a mixture of epimers and interestingly, CYP170A1 has also been shown to also be a terpene synthase converting FPP into farnesene.<sup>61,62</sup> This transformation itself does not seem to be physiologically relevant but perhaps may play a regulatory function as binding of farnesyl pyrophosphate, an albaflavenone precursor, can alter the activity of the P450.<sup>62</sup> In contrast, CYP110C1, found in cyanobacterium *Nostoc* sp. strain PCC 7120 in an operon with a sesquiterpene cyclase, is reported to be crucial for formation of the carbon skeleton of the final product (Fig. 8B).<sup>63,64</sup> The cyclase forms monocyclic germacrene A and co-expression of the cyclase with the P450 results in a new bicyclic oxygenated product. It is proposed that P450 mediated epoxidation is followed by intramolecular cyclisation. No redox partners were found in this operon but a *Nostoc* sp. ferredoxin/reductase pair were found to be the best *in vivo* partners for heterologous activity in *E. coli*. Finally, a completely non-oxidative function has been attributed to a P450 found encoded along with a terpene cyclase in *S. clavuligerus*. The cyclase produces (+)-T-muurolol when

heterologously expressed but when similarly expressed with the native, upstream P450 a structurally quite different sesquiterpene, (–)-drimenol, is produced *via* a mechanistically distinct pathway; the molecular basis of this remains to be resolved (Fig. 8A).<sup>65–67</sup>

**3.1.7 Unusual, multistep biosynthetic transformations.** A small number of well characterised terpene biosynthetic pathways display the true potential of P450s as oxidative catalysts, utilising them for more than simple oxygen transfer reactions. In the biosynthesis of the sesquiterpene antibiotic pentalenolactone by *S. avermitilis* two different transformations are P450 catalysed. The first utilises the P450 PtII and results in the conversion of an allylic methyl group of pentalene to a carboxylic acid moiety (Fig. 9A).<sup>68</sup> *In vitro* reconstitution experiments only yielded the corresponding aldehyde intermediate although it is unclear whether this was due to the *E. coli* derived redox partners or the biosynthetic requirement for a separate aldehyde dehydrogenase.<sup>68</sup> Surprisingly, the acid then subsequently undergoes a non-heme iron oxygenase (PtII) (and not a P450)




Fig. 8 Biosynthetic roles of bacterial P450s in sesquiterpene biosynthesis. Examples of P450 modified sesquiterpene (A) and proposed oxidative cyclisation of germacrene A by CYP110C1 (B). Oxygens incorporated through the actions of P450s are indicated in red.






Fig. 9 Examples of P450-mediated transformations in the biosynthesis of sesquiterpenes (A) and the proposed mechanism of the P450-mediated oxidative rearrangement in the biosynthesis of the sesquiterpene antibiotic pentalenolactone (B). P450 incorporated oxygens are indicated in red.

catalysed methylene hydroxylation. The final step in pentalenolactone biosynthesis involves an unusual oxidative rearrangement (Fig. 9B)<sup>69</sup> in which it can reasonably be proposed that compound I of the P450 (PenM (CYP161C3) and PntM (CYP161C2) are orthologs from *S. exfoliatus* UC5319 and *S. arena* TU469, respectively) abstracts a hydrogen atom from the substrate, pentalenolactone F, to yield a radical intermediate. Rebound of the compound II hydroxyl onto this radical is sterically disfavoured and instead electron transfer to yield the corresponding neopentyl cation occurs; this cation then undergoes 1,2-methyl migration and proton loss to yield the product.<sup>70</sup> Remarkably, CYP105D7 from *S. avermitilis* is known to hydroxylate the corresponding methylene of a different pentalene without rearrangement (Fig. 9A), presumably due to reaction on the sterically more accessible, diastereomeric face of the bicyclic substrate.<sup>70,71</sup> Site directed mutagenesis and substrate analogue studies failed to reveal any special features of the protein or substrate required for the rearrangement beyond steric encumbrance of the radical intermediate.<sup>70</sup>

Perhaps no biosynthetic pathway better displays the catalytic potential of P450 mediated oxidations than that of the gibberellins.<sup>72</sup> The pathway to these important signalling molecules

has independently evolved in plants, fungi and in some bacteria, the latter of which are plant symbionts or pathogens.<sup>72</sup> These diterpene derived plant phytohormones undergo a number of remarkable P450 mediated transformations (Fig. 10). CYP117 mediates the early regio- and chemospecific transformation of the C19 methyl group into a carboxylic acid moiety by three sequential oxidations proceeding *via* alcohol and aldehyde intermediates.<sup>72</sup> Next CYP114, utilising a co-encoded ferredoxin redox partner, converts a cyclohexane into a carboxy cyclopentane.<sup>72</sup> This unusual, three-step reaction is thought to proceed *via* an initial hydroxylation followed by a semi-pinacol rearrangement of an  $\alpha$ -hydroxy cation. Such a species might arise from the usual H atom abstraction by compound I, with steric inhibition of the rebound step as seen in pentalenolactone (*vide supra*) formation leading to electron transfer and cation generation. Conversion of the immediate formyl product to the acid then follows a standard pathway. It is interesting to note that the C19 carboxylate formed previously is thought to be important in this transformation despite its distal nature. CYP112 then catalyses another two-step regiospecific conversion of a methyl group into an aldehyde intermediate.<sup>72</sup> This compound then presumably undergoes oxidative loss of the




Fig. 10 Remarkable P450-mediated transformations found in gibberellin biosynthesis. Fd = gibberellin ferredoxin, SDR = gibberellin short-chain dehydrogenase/reductase. P450-catalysed reactions are indicated in red.



carboxylic acid moiety catalysed by CYP112, perhaps mediated by a ferric peroxo P450, to yield a carbocationic intermediate which then forms a lactone with the C19 carboxylate installed by CYP117. Such a loss of the carboxy moiety may initially generate a radical intermediate but again steric inhibition of rebound would be required to could promote cation formation. The final P450 involved in the gibberellin pathway is CYP115 that is required to form gibberellin 4, the bioactive hormone, and it catalyses the last step in the pathway. Almost anticlimactically, this is a simple regio- and stereospecific hydroxylation of a methylene group.<sup>73</sup>

### 3.2 Fatty acid metabolism

Fatty acid metabolism by cytochrome P450s is one of the most commonly reported reactions for this enzyme class. The relevance of such transformations to biosynthetic pathways and even the actual role of the P450 enzyme in question is not always clear, however, as fatty acids make excellent, flexible and hydrophobic substrates that can interact with many P450 active sites. None the less, there are several well characterised examples of bacterial P450 enzymes that specifically metabolise fatty acids, and even in cases where the relevance of the reaction to the organism is unclear, significant mechanistic insights into P450 function have been gained.

The hydroxylation of fatty acids remains the major reaction that is seen in bacterial P450s that act against such substrates (Fig. 11).<sup>74,75</sup> Due to the relative scarcity of structural motifs within fatty acids, the selectivity of hydroxylation in such cases is often lower than is seen for most biosynthetic transformations, with the exceptions to this rule being if the site to be hydroxylated is close to either the carboxylic acid moiety ( $\alpha/\beta$ -positions) or the terminal methyl group ( $\omega$ -position) of the fatty acid. In P450s with the requirement to specifically perform the oxidation of the energetically more challenging methyl group over neighbouring methylene groups, a highly specific active site architecture is required to restrict access of the fatty acid chain to the active site oxidant. Such an active site architecture has been resolved for CYP124 from *M. tuberculosis*, where selective hydroxylation of a fatty acid methyl group in iso-branched chain fatty acids is enabled by a highly specific fatty acid binding channel that orients the fatty acid perpendicular to the heme plane combined with significant conformational restriction in the vicinity of the heme itself.<sup>76</sup> CYP124 does not display as high a selectivity for  $\omega$ -oxidation of straight chain fatty acids, although the activity for these substrates is several orders of magnitude below that of branched chain substrates and implicates a role of CYP124 in branched chain fatty acid metabolism.<sup>76</sup>

Possibly the most well studied examples of  $\omega$ -hydroxylating P450s are the mammalian CYP4A class, and studies on these enzymes have shown that steric restriction around the active site account for the selectivity of this subfamily.<sup>77</sup> One bacterial P450 subfamily that displays a similar level of selectivity for the  $\omega$ -oxidation of straight chain fatty acids is the CYP153A subfamily, with subfamily members characterised as having very high selectivity for methyl oxidation over that of




Fig. 11 Examples of P450 enzymes involved in bacterial fatty acid metabolism, indicating the regiospecificity of oxidation displayed by these P450 in the metabolism of fatty acid substrates. Colours indicate the P450 enzyme responsible to the oxidation of the fatty acid chain at these specific positions.

neighbouring methylene groups.<sup>78</sup> CYP153A enzymes have been investigated by a number of groups due to potential interest from a biotechnological perspective, which is also heightened by observations that these P450s can also accept alkanes as substrates and produce terminal alcohols as well as  $\alpha,\omega$ -diols.<sup>79–82</sup> In the case of diol production, further oxidation has also been detected (*i.e.* to the aldehyde), which appears to increase with chain length of the substrates and probably stems from higher substrate affinity in these cases.<sup>80</sup> Production of the aldehyde has also been reported as a minor side product in experiments with CYP4A enzymes,<sup>77</sup> and demonstrates the effects that even minor side reactions can have over long reactions times when all of the initial fatty acid substrate has been converted into an intermediate species.

One of the best known examples of a cytochrome P450 is P450<sub>BM3</sub> from *Bacillus megaterium*.<sup>83,84</sup> This P450 has received a great deal of attention due to its substrate promiscuity and rapid turnover rate, making it effectively a bacterial equivalent of a xenobiotic metabolising P450 enzyme – albeit a very fast enzyme that is easily amenable to expression, mutation and scale up. Many of the favourable properties of P450<sub>BM3</sub> stem from the fact that it is a naturally existing fusion protein, where the FMN and FAD containing redox partners needed to supply electrons to the P450 domain (known as BMP) are fused into one polypeptide chain.<sup>85</sup> This arrangement leads to the rapid rates of catalysis for P450<sub>BM3</sub>, and has inspired significant work to identify more natural P450 fusion proteins as well as attempts to generate synthetic P450-fusion proteins to obtain enzymes with more favourable catalytic properties. One consequence of this fusion arrangement is that P450<sub>BM3</sub> appears to be active as a dimer, with electron transfer occurring in an intermolecular fashion.<sup>86–88</sup> P450<sub>BM3</sub> has long been reported to oxidise a range of fatty acid substrates, with hydroxylation focussed on the methylene groups at the terminus of the fatty acid chain ( $\omega-1$  to  $\omega-3$ ).<sup>89–91</sup> Increasing chain length alters this distribution and leads to increased oxidation at sites more remote from the



$\omega$ -position. The stereochemical purity of these alcohol products can be very high (>99% ee) favouring the *R*-enantiomer, although the enantiopurity of the product alcohols decreases with increasing distance from the terminal methyl group.<sup>92–94</sup> The mechanism of P450<sub>BM3</sub>-mediated hydroxylation has been probed using so-called radical clocks, in which the ring opening of cyclopropyl probes in response to an intermediate radical species prior to oxygen rebound provided strong evidence for a distinct substrate centred radical as opposed to a concerted process.<sup>95–97</sup> Long incubations of fatty acids with P450<sub>BM3</sub> can lead to the isolation of products that have undergone several rounds of oxidation, producing ketone, diol and hydroxyketone products,<sup>89,90</sup> but unlike systems in which sequential oxidations are required (such as P450<sub>sc</sub> or P450<sub>Biol</sub>, *vide infra*) the affinity of the enzymes for hydroxylated fatty acids is significantly reduced over the parent fatty acids themselves. P450<sub>BM3</sub> is also able to epoxidise unsaturated fatty acid substrates, with the relative positioning of the alkene with regards the  $\omega$ -position of the fatty acid either dictating complete epoxidation, a mixture of epoxidation and hydroxylation or complete hydroxylation.<sup>98</sup> Such effects have also been observed when thiofatty acid probes were used to investigate the effect that ease of oxidation has on both product regioselectivity and stereospecificity, which show that centres that are more easily oxidised can significantly influence both these parameters.<sup>99</sup> The inclusion of methyl groups within a fatty acid chain also provoke alterations to the regiochemistry of P450<sub>BM3</sub> oxidation, which is due to a combination of steric and electronic effects in these cases.<sup>100</sup> The oxidation of such substrates has been suggested as a possible natural reaction for this P450, although as it stands it is still not completely clear what role this remarkable P450 plays within *B. megaterium*.<sup>83</sup>

Other bacterial P450s that utilise fatty acid substrates display important examples of diversity within such enzymes. CYP105D5 from *Streptomyces coelicolor* has also been demonstrated to perform the hydroxylation of fatty acids in a similar manner to that seen with P450<sub>BM3</sub>.<sup>21</sup> In the case of this P450, reconstitution of activity could be achieved using native ferredoxin and flavoprotein ferredoxin reductase enzymes from *S. coelicolor* itself,<sup>21</sup> which serves to highlight the ability of P450s to interact and accept electrons from redox partners within the cell that may not always be closely associated with the P450. CYP119 is an example of an orphan P450 like P450<sub>BM3</sub> whose physiological role is unclear. What makes this P450 of great interest is that it was isolated from the thermophilic archaea *Sulfolobus acidocaldarius* and as such displays a much higher tolerance to elevated temperatures compared to mesophilic P450s (this P450 is included here in this review partially due to the widespread misconception that this is a bacteria).<sup>101,102</sup> The origins of the high thermal stability of this P450 appear strongly connected with aromatic stacking interactions within the protein,<sup>103</sup> whilst the ability to combine CYP119 with a thermostable redox system (comprising a ferredoxin and a 2-oxoacid:ferredoxin oxidoreductase) has been shown to significantly boost activity at 70 °C.<sup>104</sup> CYP119 is able to oxidise substrates other than fatty acids and has also demonstrated the ability to directly use hydrogen peroxide to support such oxidations.<sup>105</sup>

CYP119 has also been highly useful in mechanistic investigations into P450 mechanism and reactivity, with the Green group first demonstrating the conclusive identification and characterisation of the key P450 reactive intermediate – the central iron-oxo/ferryl intermediate known as compound I – using this enzyme.<sup>15</sup> Further examples of P450s isolated from bacteria that inhabit extreme environments include CYP261C1/2D1 that were isolated from *Photobacterium profundum* SS9 (ref. 106) and *Moritella* sp. PE36 (ref. 107) that live in a deep-sea environment. These P450s display a pressure-dependent equilibrium between two enzymatic states that appear to be related to control of water access to the P450 active site, with the “restricted access state” hypothesised to be transient in P450s not subjected to such extreme pressures in which protein hydration is favoured. These examples underline the importance of examining enzymes from extremophiles, as their properties not only inform on the adaptations required to tolerate such conditions but also provide insights into the mechanism of mesophilic enzymes.

Several bacterial P450s that oxidise fatty acids have been identified that can use hydrogen peroxide as an oxidant. Both P450<sub>SP $\alpha$</sub>  (CYP152B1) from *Sphingomonas paucimobilis*, which regio- and enantioselectively catalyses the *S*-hydroxylation of the  $\alpha$ -position of long chain fatty acids,<sup>108–110</sup> and P450<sub>BS $\beta$</sub>  (CYP152A1) from *Bacillus subtilis*, which catalyses the hydroxylation of long chain fatty acids to produce a 3 : 2 mixture of  $\beta$ -*R*- and  $\alpha$ -*S*-hydroxylated products, utilise hydrogen peroxide as an oxidant. Specific arginine (R241/R242) residues in P450<sub>SP $\alpha$</sub>  and P450<sub>BS $\beta$</sub>  are crucial as they bind the carboxylate of the fatty acid to position the substrate above the heme for oxidation in both cases.<sup>111,112</sup> Moreover, the carboxylic acid moiety appears to play a role in the generation of compound I from hydrogen peroxide in these P450s, which is an important example of substrate-assistance in the P450 active cycle.<sup>111–113</sup> The regioselectivity of P450<sub>SP $\alpha$</sub>  appears to be maintained through the channel that orients the fatty acid within the active site, as mutations corresponding the P450<sub>BS $\beta$</sub>  active site are unable to switch regioselectivity towards the  $\beta$ -position.<sup>111</sup> The opposite is true for mutations to the P450<sub>BS $\beta$</sub>  active site, which are capable of switching the regiochemistry of oxidation by this P450 towards the  $\alpha$ -position.<sup>111</sup> The use of hydrogen peroxide as an oxidant means that there is not the need to interact with redox partner proteins, and this is reflected in an extended loop prior to the axial cysteine ligand on the proximal face of the heme coupled with a predominant negative charge, which differs to P450s that interact with redox partner proteins.<sup>111,112</sup> The use of peroxide by these P450s accounts for their rapid rate of turnover and also serves to explain the high levels of interest in such enzymes as potential biocatalysts, although inactivation by high levels of peroxide can limit the usefulness of this approach.<sup>114</sup> An alternate solution has been demonstrated in the case of the related  $\alpha$ -hydroxylase CYP152A2 from *Clostridium acetobutylicum*, in which reconstitution with a functional redox partner chain was able to improve the catalytic properties of this enzyme.<sup>114</sup> Thus, the relevance and use of hydrogen peroxide as an oxidant in P450-mediated transformations always needs to be tested in comparison to a redox enzyme pathway in order to deliver the optimal system for study.



A further example of P450 diversity in bacterial fatty acid metabolism is provided by OleT (CYP152L1) from *Jeotgalicoccus* sp. ATCC 8456, which catalyses the oxidative decarboxylation of fatty acids to generate terminal alkenes.<sup>115,116</sup> OleT has a similar structure to P450<sub>SPz</sub> and P450<sub>BSB</sub>, including the extended loop near the conserved cysteine ligand and the presence of an arginine residue in the active site to coordinate to the carboxylate of the fatty acid.<sup>116,117</sup> The decarboxylation of fatty acids by OleT is supported both by peroxide and electron transfer partners, and has been extensively investigated due to the unusual nature of the reaction and the potential to use such an enzyme for biofuel production.<sup>115–121</sup> Mechanistically, it has been demonstrated that this enzyme utilises the highly reactive compound I as an intermediate in the oxidation, with a comparatively long-lived compound II species also being detected during the course of the reaction rather than the typical oxygen rebound pathway.<sup>120,121</sup> OleT serves as an important example of how bacterial P450s can perform atypical P450 chemistry despite high levels of structural and sequence similarity to related P450s that perform more standard hydroxylation chemistry.

One example of fatty acid oxidation that relies upon the selective oxidation of the middle of the fatty acid chain is that performed by P450<sub>BioI</sub>, which is found in the biotin operon of various species of *Bacillus*.<sup>122,123</sup> The role of this P450 is to generate pimelic acid (or a biological equivalent), a C<sub>7</sub> diacid precursor of biotin biosynthesis, from long chain fatty acids.<sup>74,123,124</sup> Mechanistically, this P450-catalysed multiple step oxidation proceeds *via* two sequential hydroxylations to generate a vicinal diol, which is then cleaved by the P450 to generate a C<sub>7</sub> acid/aldehyde product that then undergoes rapid oxidation to the desired diacid.<sup>125</sup> This mechanism resembles that utilised by P450<sub>Sec</sub>, the human enzyme that cleaves the side chain of cholesterol during steroid biosynthesis, which has been investigated in detail due to the importance of steroid biosynthesis for human health.<sup>124</sup> The activity of P450<sub>BioI</sub> against free fatty acids can be reconstituted, but this oxidation proceeds with low selectivity for in chain cleavage: rather, such reactions afford *R*-hydroxylated fatty acids with the site of oxidation close to (but not including) the  $\omega$ -terminus of the fatty acid.<sup>125,126</sup> The situation dramatically alters, however, when P450<sub>BioI</sub> catalyses the oxidation of fatty acids bound to acyl carrier protein (ACP).<sup>123</sup> In these cases, the production of the desired diacid product proceeds with complete selectivity. A crystal structure of the P450<sub>BioI</sub>-ACP complex – the first such complex to be isolated and structurally characterised – clearly demonstrated how the selective oxidation of ACP-bound fatty acids by P450<sub>BioI</sub> occurs.<sup>127</sup> In the complex structure, the phosphantethine arm of the ACP upon which the fatty acid is bound projects in towards the heme of the active site, and is closely coordinated *via* electrostatic interactions that lock the position of this arm in place like a ruler above the heme.<sup>127</sup> The active site, which is almost exclusively comprised of large, hydrophobic amino acid residues, then ensures that the fatty acid chain adopts a U-shaped conformation over the heme, with the bottom of the “U” comprising the C7 and C8 atoms of the fatty acid that are then closest to the heme for subsequent

oxidation.<sup>127</sup> The utilisation of a carrier protein in the substrate of P450<sub>BioI</sub> demonstrates that P450s can act against a wide range of substrates – even protein bound substrates – and that carrier protein bound substrates need to be considered when investigating P450s that are involved in systems that contain carrier proteins (such as polyketide synthases and non-ribosomal peptide synthetases (*vide infra*)).<sup>74,128</sup>

### 3.3 Alkaloid biosynthesis pathways

Alkaloids are secondary metabolites, generally biosynthesised from amino acids, which contain at least one nitrogen atom that is generally part of a heterocycle. Interest in alkaloids is often dependant on their pharmacological applications and these frequently drive investigations into their biosynthesis. Historically, alkaloids were commonly derived from plant sources, but are now known to be generated by a number of different organisms, including bacteria and fungi. Nevertheless, there are still limited examples of alkaloids biosynthesised by bacterial species and consequently, there are very few instances of P450s involved in the alkaloid biosynthesis in these organisms. However, this scarcity has not limited the unusual reactions that can be performed these P450s. Alongside the typical carbon hydroxylation reactions, bacterial P450s can execute *N*-hydroxylations and form both carbon–carbon and nitrogen–carbon bonds in the generation of alkaloids.

NzSA is an example of a P450 that catalyses a classical carbon hydroxylation reaction (Fig. 12). In *Streptomyces* sp. MA37, neocarazostatin B, a tricyclic carbazole alkaloid derived from *L*-tryptophan, is converted to neocarazostatin A triol *via* hydroxylation at C10.<sup>129</sup> Two genes (NozD and E) encoding putative P450s have also been identified in the genome of *Nocardioopsis* sp. CMB-M0232 and are proposed to be involved in the biosynthesis of nocardioazines A and B. Like neocarazostatin, these alkaloids are also derived from *L*-tryptophan, but in this case two *L*-tryptophan molecules combine to produce a cyclo-dipeptide.<sup>130</sup> NozD and E are proposed to catalyse carbon hydroxylation and epoxidation in the final stages of nocardioazine biosynthesis,<sup>130,131</sup> but further biochemical studies are necessary to determine the exact function of these enzymes (Fig. 12).

RauA (CYP1050) provides a rare example of a P450-catalysed *N*-hydroxylation in the production of an aurachin alkaloid antibiotic, aurachin RE from *Rhodococcus erythropolis* JCM 6824 (Fig. 12). The hydroxylation on the nitrogen of the quinolone ring is crucial as it is essential for the antibacterial activity of the molecule and is the final step of its biosynthesis.<sup>132,133</sup> Conversely, in other species that produce these alkaloids this oxidation is not performed by a P450. *Stigmatella aurantiaca* Sg a15 generates aurachin C, which is structurally very similar to aurachin RE, lacking only one hydroxyl moiety in comparison. The absence of a P450 in the genome of *S. aurantiaca* and genetic knockout studies suggest a Rieske [2Fe–2S] oxygenase is utilised for this oxidation rather than a P450.<sup>134,135</sup>

The most intriguing alkaloid transformations are those catalysed by the P450s involved in the biosynthesis of the indolo-carbazole alkaloids, rebeccamycin and staurosporine. These






Fig. 12 Biosynthetic roles of bacterial P450s in alkaloid biosynthesis. Oxygen atoms incorporated as a result of P450 activity are indicated in red.

include the StaP (CYP245A1) and RebP (CYP245A2), enzymes that catalyse an intramolecular carbon–carbon coupling reaction, and StaN (CYP244A1), which is responsible for the formation of a carbon–nitrogen bond in staurosporine (Fig. 13). The biosynthesis of both highly similar indolocarbazoles begins with the dimerisation of two imines derived from *L*-tryptophan (or the dichlorinated version in the case of rebeccamycin) catalysed by the hemoproteins StaD or RebD.<sup>136</sup> The P450s StaP or RebP are then responsible for catalysing the aryl–aryl coupling reaction to create a new central ring.<sup>137,138</sup> Crystal studies have suggested, due to the potentially limited movement of the substrate within the active site, that a one-electron oxidation would be favoured over the typical P450 hydroxylation.<sup>139</sup> This would facilitate proton abstraction from the indole nitrogen, which is followed by a second one-electron oxidation that triggers radical migration resulting in a formation of a new C–C bond. The required second indole proton abstraction could occur either before or after the formation of the new bond. Further work has also suggested that if the substrate does indeed have reduced access to the heme iron it

could employ a histidine (H250) in conjunction with two water molecules to catalyse this C–C bond formation.<sup>140</sup> Initial studies originally proposed that the subsequent oxidative decarboxylations were also catalysed by StaP or RebP. However, although it has now been established that these reactions can occur non-enzymatically<sup>137</sup> they must be enzymatically-controlled in order to generate the desired product.<sup>137,141,142</sup> For rebeccamycin the oxidation is facilitated by RebC, which produces 1,11-dichloroacryiaflavin A and excludes the generation of all other products that can be formed in the absence of the enzyme. In contrast, StaC mediates a 4-electron oxidation to generate exclusively K252c the aglycone core that forms staurosporine. Finally, the biosynthesis of staurosporine also requires a second P450, StaN to initiate the formation of the second carbon–nitrogen bond between the sugar and the aglycone core.<sup>143,144</sup> First, a glycosyltransferase StaG catalyses formation of the N-glycosidic bond that attaches the deoxy-sugar to the aglycone K252c to produce holyrine A. It is proposed that a StaN-mediated hydroxylation of the sugar moiety of holyrine A, followed by elimination of water creates




Fig. 13 Roles of P450 enzymes in the biosynthesis of the indolocarbazole alkaloids rebeccamycin and staurosporine. P450 enzymes are in bold, the P450-catalysed reactions are indicated in red.



an oxonium cation primed for attack by the nitrogen and consequently the formation of the second carbon–nitrogen bond. Alternatively, the oxonium ion may be formed directly from the radical intermediate generated by compound I H atom abstraction.

### 3.4 Shikimate biosynthesis pathways

Shikimate biosynthesis involves the production of many compounds that contain aromatic amino acids and other molecules containing polyphenols. Traditionally, the shikimate pathway is associated with the production of lignins in plants and it has been proposed that bacteria are essential in the breakdown of these molecules in nature. Preliminary genomic analysis of bacteria-mediated lignin degradation has indicated that P450s in *Rhizobium* sp. strain YS-1r may be involved in this process.<sup>145</sup> Bacterial P450s involved in biosynthetic pathways that include shikimate metabolites have been found associated with non-ribosomal peptide synthetases (NRPS; *vide infra*) and in alkaloid biosynthesis (*vide supra*). These enzymes catalyse the hydroxylation of aromatic amino acids such as tyrosine and tryptophan. However, more complex P450 reactions catalysing oxidative biaryl coupling during the generation of melanin are also known.

P450<sub>mel</sub> (CYP107F1) from *Streptomyces griseus*, named for its role in the production of melanin, is an example of one of a P450 that catalyses one of these more complex reactions. It catalyses the oxidative coupling of two 1,3,6,8-tetrahydronaphthalene (THN) subunits to create 1,4,6,7,9,12-hexahydroperylene-3,10-quinone (HPQ) (Fig. 14).<sup>146</sup> These HPQ units then autopolymerise to form HPQ-derived melanin, which is unlike other melanins that are typically formed from dihydroxyphenylalanine (DOPA) subunits. Again, like P450s such as CYP158 (*vide infra*), the formation of this new aryl–aryl bond is thought to occur *via* the creation of a phenolate radical and subsequent proton coupled electron transfer.

### 3.5 Polyketide (PKS) biosynthesis

Polyketides form one major class of secondary metabolites, and include many important examples such as the antibiotic erythromycin, the antifungal amphotericin, the immunosuppressant tacrolimus or the cholesterol-lowering agent lovastatin. They are synthesised by the sequential incorporation of

malonyl-CoA extender units or derivatives into a growing polyketide chain by polyketide synthases (PKSs) through repetitive Claisen condensation reactions. Based on the architecture of the PKS, these assembly lines are divided into type I–III systems.<sup>147</sup> Type I systems are very large, multifunctional proteins, where a set of different enzymatic domains build up one module and this module is responsible for extension by one extender unit. A minimal module consists of an acyl-transferase (AT), an acyl carrier protein (ACP) and a ketosynthase (KS) domain. Further reducing domains may be present within a module, which modify the  $\beta$ -keto ester intermediate during assembly. The products are usually long polyketide chains, which remain linear or undergo further (macro)cyclisation after cleavage from the multi-enzymatic complex. In contrast, type II PKS are iteratively working enzymes, consisting of a ketosynthase, a chain length factor and an ACP. The final polyketide is then modified by cyclases/aromatases, leading basically to multicyclic compounds. PKS type III are small, multifunctional enzymes building small aromatic polyketides by the condensation of one starter unit with 2–3 extender units; furthermore, such systems are dependent on coenzyme A rather than the carrier protein domains found in other PKS systems.<sup>148</sup>

Following the biosynthesis of the polyketide backbone of the PKS system, further modifications often take place: these modifications are generally related to glycosylation, the incorporation of other functional groups or further reduction/oxidation reactions. Due to the different length of the polyketide, their various cyclisation patterns, as well as further modifications, polyketides form a very large group of structurally diverse natural products. Within their biosynthesis, P450 enzymes play crucial roles, typically related to late-stage modifications, which can have a dramatic impact on the final bioactivity of the compound. Understanding P450-catalysed reactions within PKS biosynthesis (Fig. 15) is of great interest for efforts to modify existing compounds or develop new chemotherapeutic agents as, given their structural complexity, many of these medically important compounds have to be produced *via* fermentation of producer strains rather than synthesis.

#### 3.5.1 Classic P450 transformations in PKS biosynthesis.

Due to the wide range of different compounds that can be produced by PKS machineries, it is perhaps unsurprising that the diversity of function of P450 enzymes that are found associated with bacterial PKS clusters is equally high. Whilst the roles of P450s in the biosynthesis of the macrolide products of type I PKS machineries have arguably been the most extensively investigated, P450s are also found to play a role in the formation of other types of PKS products, such as polyenes and polycyclic aromatic compounds. The most common P450 transformations in PKS biosynthetic pathways are C–H hydroxylation and alkene epoxidation: whilst the latter is perhaps unsurprising given the structures of many PKS products, the requirement for hydroxylation is somewhat less intuitive. Although PKS biosynthesis naturally provides the opportunity for the incorporation of many sites of hydroxylation within the final compound, the requirement for P450-catalysed hydroxylation




Fig. 14 Structure of melanin, the biosynthesis of which involves P450<sub>mel</sub> in the oxidative dimerization of two 1,3,6,8-tetrahydronaphthalene subunits. The bonds introduced through P450-catalysed dimerisation are indicated in red.






Fig. 15 Examples of bacterial cytochrome P450 enzymes involved in PKS metabolism. The products of P450-catalysed reactions are indicated in red.

exists to modify sites within the final compound that cannot be addressed during PKS-biosynthesis. As such, these positions very often serve as the attachment sites for additional, late stage modifications of the PKS product, most typically glycosylation.

Arguably some of the most well-known examples of bacterial biosynthetic P450s are found to catalyse such reactions, including those involved in hydroxylation reactions, as found in erythromycin (EryF and EryK)<sup>149–152</sup> and pikromycin/



neomethylmycin (PikC)<sup>153</sup> biosynthesis, along with epoxidation, as found in pimaricin (PimD)<sup>154,155</sup> and epothilone (EpoK)<sup>156</sup> biosynthesis.<sup>‡</sup> Whilst such transformations are relatively common in PKS pathways, it is important to stress that the properties of each enzyme and the reaction mechanism that they employ can vary dramatically. Some brief examples of note with regards to the examples listed above include: (1) the difference in timing of the hydroxylation reactions performed by EryF and EryK in erythromycin biosynthesis with regards glycosylation (EryF functions against the aglycone whilst EryK accepts glycosylated intermediates); (2) the difference in mechanism of oxygen activation between the P450 hydroxylases in erythromycin biosynthesis (EryK maintains a standard acid/alcohol pair within the I-helix, whilst EryF relies upon hydrogen bonds from the substrate to replace the alcohol residue, which is mutated to an alanine in this case); (3) PikC displays far greater substrate selectivity with altered product production than related P450 homologs from analogous pathways; and (4) differences in the reactive intermediate responsible for epoxidation in macrolide biosynthesis (EpoK utilizes standard compound I type chemistry, whilst PimD has been reported to make use of the preceding ferric hydroperoxy intermediate, compound 0). Thus, it can be seen that even though “classic” P450 chemistry is commonly found in PKS-mediated biosynthesis, the mechanistic details of these reactions can remain complex and diverse.

**3.5.2 Complex transformations mediated by P450s in PKS biosynthesis.** Beyond classic P450 transformations, polyketide biosynthesis offers many examples of complex P450 reaction pathways, in which multiple, sequential oxidative reactions are performed by one P450 enzyme on a single substrate. Such reactions often require extensive characterisation in order to fully elucidate the preferred reaction pathway, which can be challenging due to the complex nature of the enzymatic substrates. Examples of multiple oxidative reactions at a single site with a PKS product are most commonly found in the oxidation of methyl groups into the corresponding carboxylic acid group: examples that have been reported include those found in the biosynthesis of bongkrelic acid (BonL)<sup>157</sup> and polyene compounds like amphotericin (AmphN),<sup>158</sup> candicidin (FscP),<sup>159</sup> pimaricin (ScnG)<sup>160</sup> and rimocidin (RimG).<sup>161</sup> The probable mechanistic route for such a transformation, which is found in other P450 transformations – particularly in steroid metabolism – involves three sequential oxidation reactions, and thus alcohol and aldehyde intermediates are generated prior to the final product. One example in which a highly complex biosynthetic pathway intersects with such a P450-mediated transformation is found in borrelidin (BorI) biosynthesis.<sup>162</sup> BorI is implicated in the formation of a nitrile group found within borrelidin, and whilst transformations have been reported in which a carboxylic acid is directly converted into a nitrile group,<sup>163</sup> this appears not to be the case in borrelidin biosynthesis, where gene disruption studies indicate that BorI


only affords acid products *via* a shunt pathway. Mechanistic alternatives postulated include both alcohol<sup>164</sup> and aldehyde<sup>162</sup> intermediates playing a role in nitrile formation together with other biosynthetic enzymes, although to date the exact pathway by which the nitrile moiety is installed remains unclear. Thio-tetronate biosynthesis (mixed PKS/NRPS), specifically thio-tetronamide C,<sup>165</sup> also utilises a P450 (TtmP) to generate a carboxylic acid moiety from a methyl group, although in this case the acid group is further converted into a primary amide *via* the actions of the amidotransferase TtmN that consumes both ATP and glutamine to perform this reaction. This biosynthesis route is also unusual as it contains a ferredoxin (TtmO) that supports the activity of the P450 – in most biosynthetic clusters the P450 is not accompanied by such a redox partner, and utilizes electrons from other redox proteins within the bacterium.

Single P450 enzymes are also able to act on multiple sites within a substrate during the course of PKS biosynthesis. In the biosynthesis of daunorubicin and doxorubicin, DoxA is capable of installing an  $\alpha$ -hydroxyketone moiety during the biosynthesis of these polycyclic aromatic compounds (Fig. 16A). Mechanistically, it has been shown that DoxA prefers substrates bearing 4-methoxy groups over 4-hydroxy groups and that the reaction proceeds initially by hydroxylation at the C13 methylene position. Subsequent oxidation at this position to generate the ketone affords daunorubicin, with further oxidation of the C14 methyl group to the  $\alpha$ -hydroxyketone then giving rise to doxorubicin.<sup>166–168</sup> Other complex examples of multi-step P450 reactions (combining hydroxylation and epoxidation) have been reported in the biosynthesis of the macrolides FD-891,<sup>169</sup> mycinamycin (MycG)<sup>170</sup> and tirandamycin (TamI).<sup>171</sup> In the case of MycG, the two-step transformation preferentially begins with hydroxylation at C14, with subsequent epoxidation of the C12–C13 double bond (Fig. 16B). Substrates that have undergone epoxidation before hydroxylation are no longer able to be further processed by MycG, which means that in order to efficiently perform both transformations MycG must carefully control the orientation of the substrate such that the hydroxylation step – the chemically more challenging step – takes place before epoxidation of the double bond occurs. An even more complex process is catalysed by the P450 TamI in tirandamycin biosynthesis (Fig. 16C). In this case, TamI performs three oxidation steps that are coordinated with the action of the flavoprotein TamL. TamI performs the first reaction in the cascade, which is the hydroxylation of C10 within the TirC intermediate. This is then further oxidised by TamL at C10 to generate the ketone, which then undergoes two further TamI-mediated reactions: first, epoxidation of the C11–C12 double bond, and finally hydroxylation of the C18 methyl group to generate TirB. This example is surely one of the more impressive examples of the power and control that P450s can bring to biosynthetic transformations and also serves to demonstrate why fully unravelling such pathways can require extensive experimental endeavour.

**3.5.3 Less common P450-catalysed transformations in PKS biosynthesis.** Whilst less common, there are many more examples of P450-catalysed transformations found in bacterial

<sup>‡</sup> Epothilone biosynthesis is performed by hybrid PKS/NRPS machinery, although the majority of the machinery and the region modified by EpoK is the result of PKS mediated biosynthesis.





**Fig. 16** Examples of multi-step P450 reactions found in bacterial polyketide biosynthetic pathways. (A) Installation of an  $\alpha$ -hydroxyketone moiety during the biosynthesis of doxorubicin by the P450 DoxA. The thickness of the arrow indicates the velocity of the reaction being catalysed. (B) Hydroxylation and subsequent epoxidation by the P450 MycG involved in mycinamycin biosynthesis. (C) Three-step oxidation by P450 TamI during tirandamycin B biosynthesis. P450 enzymes are indicated in bold and the oxygen atoms introduced by P450 activity are shown in red.

PKS pathways. These extend from relatively straightforward examples of alternative chemistry performed by P450s and extend to complex multiple step processes.

**3.5.3.1 Dehydrogenation – bacillaene biosynthesis.** Bacillaene is an antibiotic produced by *Bacillus subtilis* and is produced by a large hybrid PKS/NRPS machinery that includes 16 modules (13/3, respectively) and a single cytochrome P450 (PksS/Baes).<sup>172</sup> Characterisation of both the molecules itself and the biosynthetic pathway responsible for production of this molecule were difficult, in part due to the instability of the compound and also the challenge of assigning the biosynthetic machinery to the structure of bacillaene itself. Whilst bacillaene contains two hydroxyl groups and nine double bonds, no obvious role for the P450 could be identified (either hydroxylation or epoxidation). Instead, reconstitution of the activity of this P450 using a cytosolic extract of *B. subtilis* and dihydrobacillaene indicated that the role of PksS is to introduce the double bond at C14, C15 into dihydrobacillaene (Fig. 17A), affording bacillaene itself.<sup>173</sup> Such a system is naturally highly challenging to investigate due to the difficulty in obtaining modified substrates to probe the activity of this P450, however recent work on other systems has shown that P450s are able to directly catalyse the insertion of double bonds into substrates without requiring an intermediate hydroxylation step.<sup>174</sup> Whilst the elimination of an intermediate

hydroxylated species could also represent a viable route towards the formation of hydrobacillaene (especially due to the facile nature of dehydration and the stability of the resultant conjugated alkene), the possibility remains that PksS is another example of a P450 that directly generates alkene products: it is also important to recognise that the appearance of double bonds within a final compound can also arise from the activity of P450 enzymes.

**3.5.3.2 Aromatic crosslinking – oxidative dimerisation of flaviolin.** Amongst their oxidative chemical repertoire, P450s are also capable of performing the oxidative crosslinking of aromatic rings. In PKS biosynthesis, the most well studied examples are found in the biosynthesis of pigments, which in the case of *Streptomyces coelicolor* includes the dimerisation of flaviolin performed by CYP158A2 (ref. 175) and likely by CYP158A1.<sup>176</sup> The biochemical characterisation of CYP158A2 showed that flaviolin binds tightly to this P450 and causes a type-I (activation) spectral shift in the P450.<sup>175</sup> Furthermore, the incubation of CYP158A2 and flaviolin together with a functional electron transfer chain (composed of *E. coli* flavodoxin and flavodoxin reductase) demonstrated that this P450 could produce species with a mass that corresponded to flaviolin dimers and trimers: two of the dimeric species were further characterised and this revealed that the differences between






Fig. 17 Examples of less common P450-catalysed transformations found in bacterial PKS biosynthesis. (A) Introduction of a double-bond into bacillaene by the P450 PksS. (B) Dimerisation of flaviolin by the P450 CYP158A2 *via* the 3,3'-positions and 3,8'-positions, respectively) (Fig. 17B).<sup>175</sup> The structural characterisation of this enzyme in complex with flaviolin revealed two molecules of flaviolin in the enzyme active site, with these stacked over the heme within the P450 active site. From a mechanistic perspective, the crosslinking reaction likely occurs by hydrogen abstraction from the ring closest to the heme iron, with subsequent generation of a radical species in the distal flaviolin occurring either *via* proton coupled electron transfer or electron tunnelling as has been postulated for the crosslinking reaction performed by CYP121 (*vide infra*).<sup>177</sup> A further interesting note in the investigation of CYP158 enzymes has been their use in mechanistic studies, where the Green group has been able to use these enzymes to investigate the highly reactive intermediates that are found within the P450 active cycle.<sup>17</sup>

these molecules were the positions through which the monomers were joined (*via* the 3,3'-positions and 3,8'-positions, respectively) (Fig. 17B).<sup>175</sup> The structural characterisation of this enzyme in complex with flaviolin revealed two molecules of flaviolin in the enzyme active site, with these stacked over the heme within the P450 active site. From a mechanistic perspective, the crosslinking reaction likely occurs by hydrogen abstraction from the ring closest to the heme iron, with subsequent generation of a radical species in the distal flaviolin occurring either *via* proton coupled electron transfer or electron tunnelling as has been postulated for the crosslinking reaction performed by CYP121 (*vide infra*).<sup>177</sup> A further interesting note in the investigation of CYP158 enzymes has been their use in mechanistic studies, where the Green group has been able to use these enzymes to investigate the highly reactive intermediates that are found within the P450 active cycle.<sup>17</sup>

**3.5.3.3 Tetrahydrofuran ring formation – aureothin biosynthesis.** Aureothin is a polyketide metabolite of *Streptomyces thioluteus* that

displays various activities, including antifungal, cytotoxic, and insecticidal activity. Within the biosynthesis of this compound the major mechanistic question concerns the formation of the tetrahydrofuran in the final product,<sup>178,179</sup> with comparable processes also implicated in the biosyntheses of avermectin<sup>180</sup> and platensimycin.<sup>181</sup> Several studies have now shown that this moiety is installed by the P450 enzyme AurH, which effectively is able to install two C–O bonds in order to achieve this transformation.<sup>178,179</sup> The reaction mechanism adopted by this P450 has been shown to commence with the specific *R*-hydroxylation of the C-7 methylene group, with the stereochemistry of this position then maintained in the final tetrahydrofuran ring.<sup>178</sup> Subsequently, oxidation of the C-9a methyl group occurs together with concomitant production of the tetrahydrofuran ring (Fig. 17C): the ability of AurH to oxidise C-9a has been demonstrated *in vitro*, where active site mutants of AurH that prevent oxidation of the more hindered C-7 position then lead to the isolation of C-9a oxidised derivatives not normally identified in the



biosynthetic pathway of aureothin, bearing hydroxyl, aldehyde or acid moieties.<sup>182</sup> Alteration of the starting material for AurH by changing the methylation of the precursor has shown that this P450 will perform sequential oxidation at C-7, with resultant electrocyclic formation of the pyran ring in aureopyran.<sup>183</sup> Such experiments also show the importance of substrate binding and orientation in P450 enzymes, as in the case of AurH multiple oxidations at C-7 and C-9a are both clearly possible and would lead to complex mixtures of various products if the oxidative cascade was not carefully optimized for the natural 2-step reaction.

**3.5.3.4 C-S bond formation – griseoviridin and thiolactomycin biosynthesis.** C-S bond formation is a relatively rare P450-catalysed reaction; however, a number of examples have recently been identified including two examples from bacterial PKS (mixed NRPS/PKS) biosynthesis. Griseoviridin is a streptogramin-type antibiotic produced by *Streptomyces griseoviridis* and contains a bicyclic structure that is formed by a thioether bond between the side chain of the terminal cysteine residue and the double bond of the alkene installed by the second PKS module.<sup>184</sup> A P450 (SgvP) has been implicated in the synthesis of this thioether bridge,<sup>185,186</sup> with gene disruption experiments showing the essential nature of this P450 in thioether formation (Fig. 17D).<sup>184</sup> Mechanistically, it remains unclear whether this is a diradical coupling mediated process, proceeds by initial epoxidation of the C2–C3 alkene or perhaps involves a sulfenic acid intermediate, and clarification of this pathway awaits further investigation.<sup>185</sup> The mechanism of C-S bond formation in the mixed NRPS/PKS biosynthesis of thiolactomycin – a thiotetronate antibiotic produced by several strains of *Streptomyces* and *Salinispora* – presents an even more complex case.<sup>187,188</sup> Here, the P450 TlmF has been shown to be required for the formation of the five-membered thiolactone ring present in thiolactomycin.<sup>188,189</sup> This ring, found at the C-terminus of the molecule, contains a sulfur atom that originates from the side chain of cysteine that is selected and activated by the final module of the PKS/NRPS. Following this, the exact mechanism by which the sulfur is inserted into the molecule is unclear, although the role of the P450 is believed to centre on the epoxidation of the C4–C5 double bond (Fig. 17D). Lack of P450 activity leads to an alternate product being produced, in which a six-membered thiolactone ring is formed. Two postulates then have been proposed for the fate of the intermediate epoxide: direct attack of a thiaacid to give the thiolactone; or the intermediate generation of a thiirane that then attacks the PKS bound thioester leading to the formation of thiolactomycin. Whilst further studies are clearly warranted in this highly interesting biosynthetic pathway, some evidence has been gained in support of the thiirane intermediate from the use of synthetic probes which have identified an intermediate that could result from thiirane hydrolysis.<sup>190</sup>


From these examples, it is clear that the role of P450s within PKS biosynthesis in bacteria can significantly diverge from what would be considered standard P450 hydroxylation and epoxidation chemistry. Beyond the important implications that such reactions have for potential biotechnological applications, these reactions also serve as a salient reminder for those

wishing to assign the roles of P450 identified in PKS biosynthesis clusters *in silico* to be aware of the chemical diversity that P450s can display and also highlights the importance of testing such hypotheses using experimental techniques.

**3.5.4 P450s that accept protein-bound substrates in PKS biosynthesis.** Whilst the majority of P450-mediated transformations that have been characterised in PKS biosynthesis occur against free substrates, a proportion of transformations have been demonstrated (or implicated) to occur against substrates which remain bound to ACP-domains within the PKS machinery. One of the most well characterised examples of a P450 that targets an ACP-bound PKS intermediate is CalO2 from calicheamicin biosynthesis: this P450 is responsible for the hydroxylation of the aromatic ring of the orsellinic acid portion of calicheamicin.<sup>191</sup> Evidence for the ACP-bound nature of the substrate for this P450 includes the type-1 binding spectra obtained for this P450 when using *N*-acetylcysteamide (SNAc) mimics of potential aromatic substrates, along with the tighter binding of these compounds when compared to the aromatic compounds alone.<sup>191</sup> Furthermore, the structural characterisation of CalO2 shows that this enzyme shares the highest homology with BioI, a well characterised fatty acyl-ACP lyase, whilst modelling of ACP docking to CalO2 shows that an ACP-derived linker would fit well into the active site of this P450.<sup>191</sup> Care must be taken when comparing CalO2 with other related systems that involve aromatic hydroxylation, however, as not all systems containing a P450 that perform similar oxidation reactions rely on ACP-bound intermediates (for example hydroxylation of the naphthyl group in azinomycin biosynthesis occurs on the substrate free in solution).<sup>192,193</sup> The biosynthesis of stambomycin also invokes P450 catalysed hydroxylation activity against PKS-bound substrates, with the P450 SamR0479 demonstrated to install the C-50 hydroxyl group required for macrolactonisation at the end of PKS-mediated biosynthesis.<sup>194,195</sup> The installation of the C-28 hydroxyl group by another P450, SamR0478, has also been demonstrated: analysis of shunt pathway intermediates also suggest in this case that the transformation may occur whilst the substrate is in the ACP-bound form. Reconstitution of enzymatic activity in such a case is highly challenging due to the complex nature of the proposed intermediates, which is a common challenge in investigating PKS-biosynthesis. The analysis performed in the case of stambomycin biosynthesis highlights the benefits of combining *in vivo* gene disruption experiments with analysis of <sup>18</sup>O<sub>2</sub> incorporation into such compounds during fermentation, as the latter provides strong proof of P450-mediated hydroxylation activity.<sup>194</sup> Nocardiopepsin biosynthesis (mixed NRPS/PKS)§ is another example of a P450-mediated transformation of a carrier protein bound intermediate: in this case, the installation of the C6 hydroxyl group required for macrolactonisation of the compound through epoxidation of the C5–C6 double bond by P450 NsnF and

§ The intermediate postulated to be the substrate of NsnF is strictly bound to a PCP-domain, as the terminal module of the nocardiopepsin mixed PKS/NRPS is an NRPS module; however, as the substrate of the P450 is a PKS-portion of the molecule, this compound is included in the PKS section.





**Fig. 18** Examples of P450-mediated protein recruitment during PKS modification. (A) The activity of the glycosyltransferase DesVII in methymycin/pikromycin biosynthesis is dependent upon the presence of the P450-like protein DesVIII. Subsequently, the compounds are then hydroxylated by the P450 PikC. (B) In erythromycin biosynthesis, the glycosyltransferase EryCIII interacts with the P450-like protein EryCII. P450 catalysed reactions are shown in red and the P450 enzymes are indicated in bold.

subsequent hydrolysis of the epoxide by NsnG.<sup>196</sup> As macro-lactonisation appears necessary for the cleavage of the compound from the PKS/NRPS assembly line (due to the lack of a terminal thioesterase domain, which is replaced by a condensation domain) this hydroxylation would be expected to be performed whilst the intermediate is bound to the assembly line, although this has yet to be verified *via* reconstitution of the relevant enzymes. A further example of a ACP-bound oxidation by a P450 enzyme has been postulated to occur in the biosynthesis of aurafuron A, where the P450 AufB has been implicated in formation of the furanone moiety.<sup>197</sup> This process has been postulated to begin with AufB-catalysed hydroxylation at C2 followed by subsequent oxidation of this intermediate by the monooxygenase AufJ affording a ketone at C2 with concomitant cleavage of the intermediate from the ACP.<sup>197</sup> Lending support to the substrate for AufB being a PKS-bound intermediate is the homology AufB has to P450s NikQ and NovI, both of which function against PCP-bound amino acids in NRPS-mediated biosynthesis (*vide infra*). As with the majority of such P450-mediated reactions that are proposed to occur against PKS-bound intermediates clarification of the role of AufB awaits further experimental analysis.

**3.5.5 P450-mediated protein recruitment during PKS modification.** One final role for P450 enzymes within PKS biosynthesis that does not rely upon their ability to perform complex chemistry has been identified in several macrolide-producing bacterial PKS clusters: these systems, rather than performing oxidation chemistry, appear to have been retained as essential interaction partners for recruiting glycosyltransferase enzymes. In the first characterised example, the activity of the glycosyltransferase DesVII from methymycin/pikromycin biosynthesis was shown to be dependent upon the presence of DesVIII, which has high sequence homology with P450 enzymes (Fig. 18A).<sup>198</sup> The DesVIII protein when expressed, however, does not contain a heme cofactor as would be expected from a functionally competent P450, which indicates that the

role of this protein is recruitment and not direct catalytic activity.<sup>198</sup> The structural characterisation of a related glycosyltransferase EryCIII/P450-like protein EryCII from erythromycin biosynthesis (Fig. 18B) not only confirmed the nature of the interaction between the two proteins but in this case could show the effect of modifications on the P450-like protein that render it catalytically inactive: in addition to the lack of heme within the enzyme active site, the protein itself has been truncated from the C-terminus to the extent that the terminal helix (that normally contains the axial cysteine ligand for the heme) is completely missing.<sup>199</sup> Thus, these examples show yet again the complexity of assigning likely P450 roles within biosynthetic gene clusters and act as a reminder to keep the complex set of protein–protein interactions in such systems in mind when considering biosynthetic hypotheses.

### 3.6 Peptide biosynthesis pathways

Polypeptides are another major group of secondary metabolites in which P450s are implicated in their biosynthesis. Such peptides can be biosynthesised in a number of ways: in addition to ribosomally synthesised and post-translationally modified peptides (RiPPs), small peptides can be synthesised in a tRNA-dependent manner without the involvement of the ribosome, whilst another major class of peptide biosynthesis is performed by non-ribosomal peptide synthetases (NRPS) – megaenzymes that have no reliance on tRNA or the ribosome for peptide synthesis. In all cases, P450s in bacterial biosynthetic pathways play important roles in modifying these peptide natural products.

**3.6.1 Ribosomally synthesised and post-translationally modified peptide (RiPP) pathways.** Ribosomally synthesised and post-translationally modified peptides (RiPPs) are small peptides in which their biosynthesis starts with a ribosomally generated precursor peptide. Thus, the RiPPs contain only proteinogenic amino acids, although extensive modification to



their structure often leads these peptides to resemble those produced by NRPS machineries. After several extensive post-translational modifications, the N-terminal leader sequence is removed and the mature, active peptide is then exported from the bacterial cell. Modifications found in RiPP biosynthesis include intramolecular cyclisation such as lanthionine bridge-formation, the introduction of further functional groups into the peptide or epimerisation of amino acid residues.<sup>200–202</sup> While cytochrome P450 genes are typically common in major secondary metabolite gene clusters, they are fewer examples found in the biosynthesis of bacterial RiPPs (Fig. 19). Hydroxylation of amino acid residues – a common P450 reaction found in NRPS biosynthesis – is much less common in RiPP pathways, possibly due to the difference in substrates in each case (carrier protein bound amino acid as opposed to complex peptide). One example of hydroxylation of an amino acid residue occurs in microbisporicin biosynthesis, where the P450 MibO appears responsible for dihydroxylation of the Pro14 residue;<sup>203</sup> another example is the hydroxylation of Phe and Ile residues by the P450s TbtJ1 and TbtJ2 in thiomuracin biosynthesis.<sup>204,205</sup> A more complex example of amino acid oxidation is seen in the biosynthesis of GE37468, in which Ile8 is transformed into a  $\beta$ -methyl- $\delta$ -hydroxy-proline residue *via* the actions of P450 GetJ. This reaction would appear to follow the same path as is generally observed for the oxidation of methyl groups into carboxylic acids, although in this case the intermediate aldehyde spontaneously cyclises to generate a hemiaminal.<sup>206</sup> Thiostrepton, a complex RiPP, contains two P450s within its gene cluster, with the role of each only recently identified.<sup>207</sup> The

enzyme TsrR was shown *via* gene disruption experiments to be responsible for the dihydroxylation of the Ile10 residue within the linear peptide prior to macrolactamisation.<sup>207</sup> TsrP plays an integral role in the cyclisation of thiostrepton, where it initially epoxidises the quinaldic acid moiety within the linear precursor. The role of this P450 was initially identified by the incorporation of a fluorinated quinaldic acid moiety into the peptide, which prevented epoxidation by TsrP and also led to the retention of the leader peptide sequence.<sup>207</sup> Following epoxidation, attack of the epoxide by the amino group of Ile1 then occurs to generate the macrolactam ring, with concomitant loss of the leader peptide and generation of the C-8 hydroxyl group within the quinaldic acid moiety. These P450s are impressive examples of P450-mediated transformations and also serve to highlight the ability of P450 enzymes to selectively modify residues within large peptide substrates. A further example of an unusual P450-mediated transformation in RiPP biosynthesis has been identified in bottromycin biosynthesis: here, the P450 BtmJ has been implicated in the oxidative decarboxylation of the thiazoline ring to generate a thiazole moiety.<sup>208–211</sup> Furthermore, it would appear that this P450 is selective for the unnatural  $\delta$ -isomer of the preceding aspartic acid residue, which is believed to be highly prone to epimerisation.<sup>208</sup> Cytochrome P450s TbtJ1 and TbtJ2 from thiomuracin biosynthesis have also been re-purposed to perform novel, synthetic reactions: Bowers and co-workers were able to demonstrate that suitably modified forms of these P450s could perform selective cyclopropanation of dehydroalanine residues within complex linear and cyclic RiPP cores.<sup>212</sup> This approach




Fig. 19 Examples of P450 enzymes involved in bacterial RiPP metabolism. P450 enzymes are indicated in bold and the P450-catalysed reactions are shown in red.



demonstrates how P450s can also be engineered to not only provide specificity but also to enable non-standard transformations in complex biosynthetic systems.

**3.6.2 Nonribosomal peptide synthesis (NRPS) pathways.** In contrast to RiPPs, many peptides from microorganisms are synthesised in a RNA-independent manner by non-ribosomal peptide synthetases (NRPS). Similar to PKS system, NRPS are organised into domains that perform specific enzymatic functions and further into modules, with each module responsible for the incorporation of one specific amino acid into the peptide chain.<sup>213,214</sup> One module for peptide extension consists of at the very least an adenylation domain (A), a peptidyl-carrier protein (PCP) and a condensation domain (C), with additional modifying domains optional. One of the most important examples of optional NRPS domains are epimerisation (E)-domains, which are responsible for generating the D-configured amino acid residues that are a hallmark of NRPS-produced peptides.<sup>213,214</sup> After biosynthesis of the peptide backbone, these molecules are also typically highly modified by, for example, halogenation, acylation, glycosylation or even intramolecular crosslinking.

#### 3.6.2.1 NRPS-bound substrates

**3.6.2.1.1 Modification of PCP-bound amino acids.** In contrast to the ribosomal synthesised peptides, NRPS machineries are not limited to accepting proteinogenic amino acids, but can also activate and incorporate a wide range of unusual, non-proteinogenic amino acids (Fig. 20).<sup>215</sup> Furthermore, modified amino acids such as  $\beta$ -hydroxy amino acids have been identified in a number of non-ribosomal peptides, including the vancomycin-type antibiotics (Tyr),<sup>216–219</sup> the aminocoumarin-containing angucycline antibiotics (Tyr; novobiocin, simocyclinone, coumermycin, clorobiocin),<sup>220</sup> echinomycin (plus other compounds that contain the intercalative chromophores quinoxaline-2-carboxylic acid (QXC) or 3-hydroxyquinaldic acid (HQA));<sup>221</sup> Trp,<sup>222,223</sup> zorbamycin (Val)<sup>224</sup> and nikkomycin (His).<sup>225,226</sup> Common to all these pathways is an NRPS/P450 dependant process for generating these  $\beta$ -hydroxy amino acids for incorporation into the final natural product. This system comprises a di-domain NRPS module of an adenylation domain and subsequent PCP domain, which is responsible for selecting and activating the requisite amino acid and loading it onto the PCP-domain. This PCP-domain is then recognised by the downstream P450 enzyme, which performs the  $\beta$ -hydroxylation of the tethered amino acid. Subsequently, the modified amino acid can either be hydrolysed by a separate thioesterase domain for selection by separate NRPS machinery (as occurs for example in echinomycin or glycopeptide antibiotic (GPA) biosynthesis (Fig. 21A))<sup>227</sup> or utilised directly for further modification (as occurs in aminocoumarin biosynthetic pathways).<sup>228</sup> The P450 enzymes in these systems recognise the PCP-domain of the di-domain NRPS module rather than the loaded amino acid, with such P450s also maintaining a rigid PCP-binding site that consists of a small number of highly conserved residues, allowing the function of such P450s to be predicted largely on the basis of sequence comparison alone. A similar process is believed to be at play during the biosynthesis of hectochlorin (mixed NRPS/PKS) where the PCP-bound substrates are believed to be 2-oxo-isovaleric acid.<sup>229</sup> An example of a two-step

transformation of a PCP-bound amino acid has been suggested to occur in the biosynthesis of the cyclic peptides JBIR-34 and JBIR-35.<sup>230</sup> In this pathway, the di-domain NRPS module FmoA1 presents a tryptophan residue (or chlorinated derivative) to the P450 FmoC, which performs two oxidation reactions; hydroxylation of the indole ring as well as  $\beta$ -hydroxylation.<sup>230</sup> Cleavage of the dihydroxylated product would then be performed by the thioesterase FmoB (Fig. 25A). This dihydroxylation shares similarity to that catalysed by TxtE in thaxtomin A biosynthesis (*vide infra*), although in the case of FmoC the substrate amino acid is PCP-bound.<sup>231</sup>

P450-mediated hydroxylation of NRPS-produced peptides can also occur *via* direct hydroxylation of PCP-bound amino acids during their incorporation into the parent NRP: in the first identified case – that of skyllamycin biosynthesis<sup>232,233</sup> – P450<sub>sky</sub> (CYP163B3) was found to be responsible for the  $\beta$ -hydroxylation of L-Phe, OMe-L-Tyr and L-Leu residues attached to NRPS modules 5, 7 and 11, respectively.<sup>234</sup> P450 selectivity in this system is again based on the PCP domains involved, with tolerance for different amino acids as substrates when these were loaded onto PCP domains that are recognised by this P450.<sup>234–236</sup> A further example of this amino acid hydroxylation strategy has been identified in telomycin biosynthesis, in which the P450 enzyme Tem23 hydroxylates the Leu-10 residue during NRPS-mediated biosynthesis of the peptide.<sup>237</sup> A related strategy to this has also been invoked in hydroxylation of a PCP-bound threonine residue during actinomycin G biosynthesis, although in this case it appears as though there is a relationship between the P450 (AcmG8) and a halogenase that modifies the same position (AcmG9) that needs further clarification.<sup>238</sup> A potential modification of this strategy of targeting PCP-bound amino acids has been identified in the biosynthesis of the mixed NRPS/PKS  $\alpha,\beta$ -epoxyketone proteasome inhibitor TMC-86A.<sup>239</sup> In this case, evidence suggests that P450 TmcK introduces a double bond into the side chain of Leu-2 after the amino acid is PCP-bound, with further experiments no doubt required to probe this unusual PCP-bound transformation.<sup>239</sup>

**3.6.2.1.2 Phenolic coupling of PCP-bound peptides.** In addition to the relatively common P450-catalysed  $\beta$ -hydroxylation of PCP-bound amino acids, one further major class of P450-mediated transformations against PCP-bound substrates is the oxidative crosslinking of aromatic side chains within PCP-bound NRPS peptides. The most well-known compound class that exhibits multiple aromatic crosslinks that are installed by P450 enzymes are the glycopeptide antibiotics (GPAs), which include the representative examples vancomycin and teicoplanin.<sup>240–243</sup> The intramolecular cyclisation reactions catalysed by cytochrome P450 enzymes lead to a specific tertiary structure able to bind to the terminal D-Ala-D-Ala motif of the bacterial cell wall precursor lipid II and thereby blocking cell growth. As last-line antibiotics, they are the major treatment against multiresistant gram-positive pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA). In these NRPS-biosynthesised heptapeptides, the three (vancomycin-type) or four (teicoplanin-type) crosslinks have been demonstrated to be inserted *in vivo* by cytochrome P450 enzymes, with each ring






Fig. 20 Examples of P450 enzymes involved in the modification of PCP-bound amino acids and peptides in NRPS metabolism. P450 enzymes are indicated in bold, the P450-catalysed reactions are shown in red and the phenolic crosslinking of PCP-bound peptides are shown in magenta.


installed by a specific P450.<sup>244–248</sup> Furthermore, gene disruption experiments determined that a specific order of ring installation occurs during GPA biosynthesis (Fig. 21B). Ring insertion commences with generation of the C–O–D ring by OxyB, with

subsequent activity of the optional OxyE enzyme (installing the teicoplanin-type F–O–G ring) and the essential OxyA enzyme (installing the D–O–E ring), before terminating with insertion of the AB crosslink that is catalysed by OxyC.<sup>244–249</sup> These



experiments also led to the hypothesis that the crosslinking performed by these P450 enzymes was likely to occur against NRPS bound (*i.e.* PCP-bound) peptides, which was confirmed for the OxyB enzyme from vancomycin biosynthesis by the work of Robinson and co-workers.<sup>250–252</sup> More recent work has shown that the process of P450 recruitment to the NRPS-bound peptide is more complicated than is the case for PCP-bound amino acids, with GPA biosynthesis relying on the X-domain, a conserved (albeit modified) condensation domain found between the PCP<sup>253</sup> and TE-domains in the final NRPS

module.<sup>243,254–257</sup> The X-domain has an interaction interface that specifically binds to the Oxy enzymes, with these continually binding to and releasing from the X-domain to ensure that complete crosslinking of the peptide occurs.<sup>254</sup> The X-domain is also required in the majority of cases to support efficient P450-catalysed crosslinking *in vitro*, with this requirement strictly enforced for OxyA and OxyE that act after OxyB.<sup>243,255,256,258–263</sup> Complestatin<sup>264</sup> and kistamicin<sup>265</sup> are structurally similar to GPAs, and also display several oxidative crosslinks whose generation has been ascribed to P450 enzymes, *i.e.* NRPS-bound



**Fig. 21** P450 enzymes involved in glycopeptide antibiotics biosynthesis. (A) In balhimycin biosynthesis, two  $\beta$ -hydroxytyrosine residues are incorporated into the heptapeptide compound through the actions of an NRPS. The amino acid (L-Tyr) is initially selected, activated and loaded onto the di-domain BpsD, which consists of an A- and a PCP-domain. After  $\beta$ -hydroxylation of the tethered amino acid, this is then hydrolysed from the PCP-domain by the separate thioesterase Bhp and subsequently used by the NRPS system for assembly of the heptapeptide. Incorporated OH-Tyr are indicated in the final balhimycin compound (grey). (B) Following assembly of the heptapeptide chain in GPA biosynthesis, the three (vancomycin-type GPA) or four (teicoplanin-type GPA) crosslinks of the aglycone are installed by different P450 enzymes, which occurs in a specific order when the peptide is still bound to the PCP of the last module of the NRPS assembly line. The X-domain present within the final module of GPA NRPS assembly lines is a unique interaction platform for these P450 enzymes. The P450 cyclisation cascade first proceeds with installation of the C–O–D ring by OxyB, then F–O–G ring (teicoplanin-type GPAs only) insertion catalysed by OxyE, the D–O–E catalysed by OxyA and finally the A–B ring formation catalysed by OxyC. The P450-catalysed crosslinkings are indicated in purple. A, adenylation domain; PCP, peptidyl carrier protein; TE, thioesterase domain; X, P450 recruitment domain.



modification with X-domain mediated P450 recruitment. The initial ring inserted in complestatin is the equivalent of the GPA C–O–D ring and is performed by the P450 enzyme ComJ, with the C–C bond formed between and Trp and Hpg residues in complestatin installed by P450 enzyme ComI.<sup>266,267</sup> Kistamicin is similar in structure to complestatin although it contains an additional A–O–B ring: curiously, only two P450 enzymes were identified in the kistamicin gene cluster, implying a dual role for one of these P450 enzymes.<sup>265</sup> Another example of a P450-mediated crosslinking of aromatic side chains within a peptide is found in arylomycin biosynthesis, in which a C–C bond is formed between the Hpg-4 and Tyr-6 residues whilst the peptide remains bound to the NRPS.<sup>268,269</sup> Here, there is no X-domain identified in the NRPS machinery, presumably due to the single P450-catalysed modification occurring in this case.<sup>268,269</sup>

**3.6.2.2 Peptide modification.** P450-catalysed modification of peptides within NRPS pathways have also been identified in numerous systems (Fig. 22), some of which share similarities with those identified in RiPP pathways.

**3.6.2.2.1 Peptide hydroxylation – TMC-86A biosynthesis.** The archetypal P450-catalysed reaction – the selective hydroxylation of unactivated C–H bonds – has also been identified in the modification of NRPS-produced peptides that occurs after cleavage of the peptide chain from the NRPS machinery (see also himastatin, *vide infra*).<sup>270,271</sup> An example of this chemistry is found in the biosynthesis of the  $\alpha,\beta$ -epoxyketone proteasome inhibitor TMC-86A (a mixed NRPS/PKS pathway), in which the P450 enzyme Tmcl performs the hydroxylation of the methyl group adjacent to the epoxy moiety in this compound.<sup>239</sup> The biosynthesis of the related compound eponemycin also contains a homologous P450 that is believed to perform the

analogous reaction; such a P450 is absent in the epoxomicin gene cluster that lacks this hydroxyl group.<sup>272</sup>

**3.6.2.2.2 Introduction of double bonds – WS9326A biosynthesis.** The P450 Sas16 is proposed to be involved in the biosynthesis of the (*E*)-2,3-dehydrotyrosine residue found in WS9326A and its derivatives (Fig. 22).<sup>273</sup> The deletion of the gene led to mutants producing a derivative containing a standard tyrosine residue without the double bond. The exact nature of the substrate of Sas16, for example whether it accepts on free tyrosine or PCP-bound intermediates thereof, requires further investigation.<sup>273</sup>

**3.6.2.2.3 Aromatic nitration – rufomycin biosynthesis.** One of the more unusual examples of a P450-catalysed transformation is the nitration of aromatic rings, which was initially identified in thaxtomin A biosynthesis in the nitration of a tryptophan residue (*vide infra*)<sup>274</sup> and has now also been reported in the nitration of a tyrosine residue in rufomycin biosynthesis.<sup>275</sup> A cyclic heptapeptide, rufomycin contains a number of unusual amino acid building blocks, with two – 3-nitrotyrosine and *trans* 2-crotylglycine – utilising P450s in their formation. 3-Nitrotyrosine is formed by the P450 RufO using nitric oxide that is formed by the neighbouring RufN nitric oxide synthase and is believed to occur prior to the amino acid being selected and activated by the NRPS machinery (Fig. 23A).<sup>275</sup> Incidentally, two further P450s have also been implicated in oxidative transformations of the cyclic rufomycin peptide, which include the epoxidation of the *N*-dimethylallyltryptophan residue and the multistep oxidation of a Leu-5 methyl group into a carboxylic acid moiety.<sup>275</sup>

**3.6.2.2.4 Heteroatom oxidation – nocardicin biosynthesis.** Nocardicin biosynthesis contains many examples of novel biosynthetic chemistry,<sup>276</sup> including several examples of





Fig. 22 Examples of P450 enzymes involved in the modification of peptides (PCP-independent) in NRPS metabolism. P450 enzymes are indicated in bold, the P450-catalysed reactions are shown in red.





**Fig. 23** P450 involved in the modification of non-ribosomal peptides. (A) In rufomycin biosynthesis, the P450 RufO catalyses the nitration of a tyrosine residue. This P450 enzyme uses nitric oxide that is formed from arginine by the nitric oxide synthase RufN. (B) In nocardicin biosynthesis, the P450 enzyme NocL performs two *N*-hydroxylation reactions, followed by spontaneous dehydration to afford the oxime. (C) In himastatin biosynthesis, there are multiple transformations catalysed by P450 enzymes. The P450 HmtT generates hexahydropyrroloindole from the 6-Trp residue in the cyclic hexadepsipeptide precursor. Subsequently, the P450 HmtN catalyses hydroxylation and finally the P450 HmtS performs the symmetrical biaryl coupling of two cyclic hexadepsipeptide precursors to generate himastatin. P450 enzymes are indicated in bold, the P450-catalysed reactions are shown in red. A, adenylation domain; C, condensation domain; PCP, peptidyl carrier protein; TE, thioesterase domain.

unusual NRPS-catalysed reactions,<sup>277,278</sup> an atypical SAM transferase<sup>279</sup> and a cytochrome P450, which has been shown to perform the oxidative transformation of the amino group of the *N*-terminal Hpg moiety into an oxime.<sup>280</sup> The P450 in question, NocL, has been shown to perform this transformation *in vitro*, with the reaction presumably following a two-step mechanism that begins with the hydroxylation of nocardicin C to 2'-*N*-hydroxy-nocardicin C. A second hydroxylation to afford 2'-*N,N*-dihydroxy-nocardicin C is hypothesised to then be followed by dehydration to afford a nitroso species that then tautomerises to provide the oxime of nocardicin A (Fig. 23B).<sup>280</sup> This transformation is analogous to the CYP79 catalysed formation of oximes from amino acids in plants, except that in this case it is coupled decarboxylation-dehydration that leads to

the nitroso intermediate.<sup>281</sup> Heteroatom oxidation by P450 enzymes has been widely reported,<sup>12</sup> and although such reactions are often found in xenobiotic metabolism, NocL serves as an important reminder that the role of P450s in heteroatom oxidation during secondary metabolism cannot be discounted.

**3.6.2.2.5 Heterocyclic ring formation.** P450 activity that generates bonds between heteroatoms and aryl groups within peptides is well known from P450s that interact directly with NRPS-bound peptides, such as occurs in GPA biosynthesis. This type of chemistry has also been identified in the biosynthesis of some examples of peptides produced NRPS machineries. In salinamide A biosynthesis (strictly a mixed NRPS/PKS), the P450 Sln10 is hypothesised to generate the linkage between the phenol of the 4-hydroxyphenylglycine residue and the (4-



methylhexa-2,4,-dienyl)glycine moiety.<sup>282</sup> The crosslinking reaction also leads to the generation of an epoxide group that includes the 4-methyl group of the (4-methylhexa-2,4,-dienyl)glycine moiety, which indicates that this may be the initial site of oxidation by this P450.<sup>282</sup> C–N bond formation to generate a new heterocycle has also been identified in the biosynthesis of lyngbyatoxin.<sup>283,284</sup> In this case, P450 LtxB has been shown to perform the *N*-alkylation of the side chain of the Trp-2 residue using the methylated amine group of the Val-1 residue. This reaction has been reconstituted *in vitro*, and this has shown that there is significant flexibility in the substrate selectivity of this P450, meaning that the valine residue can be exchanged for related amino acid residues with little effect on activity.<sup>284</sup> Mechanistically, this reaction has been postulated to include an intermediate epoxide species that – following attack of the valine amine group – undergoes dehydration to re-aromatise the indole ring.<sup>283</sup>

**3.6.2.2.6 Multiple transformations – himastatin biosynthesis.** One of the most interesting collections of P450s in NRPS-mediated peptide biosynthesis are those involved in himastatin formation; these also display the biosynthetic potential of these enzymes. In this pathway (Fig. 23C), three P450s (HmtN, HmtS and HmtT) play vital and yet highly different roles in the biogenesis of himastatin, a symmetrical dimeric cyclohexadepsipeptide antibiotic.<sup>270,271</sup> The first P450 to act in this pathway is HmtT, which generates hexahydropyrroloindole from the Trp-6 residue in the cyclic hexadepsipeptide precursor, a reaction that has similarities to that of LtxB (*vide supra*) in lyngbyatoxin biosynthesis<sup>283,284</sup> and has been suggested to occur *via* epoxidation of the indole ring of the tryptophan moiety.<sup>270</sup> The second P450, HmtN, subsequently performs a more standard – albeit still impressive – selective hydroxylation of the cyclic hexadepsipeptide precursor to produce the  $\gamma$ -hydroxy moiety of the 3-piperazine residue.<sup>270,271</sup> Finally, HmtS then performs the symmetrical biaryl coupling of two cyclic hexadepsipeptide precursors *via* their hexahydropyrroloindole moieties,<sup>270</sup> a reaction with parallels to these found in flaviolin and GPA biosynthesis.<sup>175,243</sup> The examples of the diversity of reactions displayed not only within himastatin biosynthesis but within all NRPS-biosynthetic pathways discussed here shown how important P450s are in the production of diverse secondary metabolites, and also gives an indication of the diversity of roles that should be considered when assigning potential roles to P450 enzymes in newly identified examples of such biosynthetic gene clusters.


**3.6.3 Diketopiperazine (DKP) biosynthesis.** Another subgroup of peptide-related secondary metabolites are diketopiperazines (DKPs) and their derivatives. The heterocyclic core of 2,5-diketopiperazines results from the condensation of two  $\alpha$ -amino acids catalysed by either an NRPS pathway or by the action of tRNA-dependent cyclodipeptide synthases (CDPS). Whilst the DKP subunit forms an integral part of several secondary metabolites isolated from fungi, there are relatively few described from bacterial species.

**3.6.3.1 tRNA-dependent DKP biosynthesis pathways.** The tRNA-dependent cyclodipeptide synthases (CDPS) use

aminoacyl-tRNAs instead of the AMP-activated amino acids that are generated during in NRPS-mediated biosynthesis.<sup>285</sup> Thus, the CDPS pathway connects primary and secondary metabolism by “hijacking” aminoacyl-tRNAs, with the result that their substrate selection is restricted to natural proteinogenic amino acids. Following condensation and cyclisation of two amino acids, the cyclic dipeptide can also undergo further modifications, several of which have been identified to be performed by cytochrome P450s. One example from *Bacillus subtilis* is the biosynthesis of pulcherrimin, which is involved in iron chelation. Commencing from cyclo(L-Leu-L-Leu), the P450 CypX performs a series of sequential oxidation reactions on the DKP ring itself, resulting in the formation of pulcherrimic acid in which both nitrogen atoms have been oxidised to *N*-oxides and the DKP ring itself has been aromatised.<sup>286</sup> Chelation with iron then affords the final red pigment pulcherrimin (Fig. 24A). Mycocyclusin is another example of a P450-modified bacterial DKP that is produced by *M. tuberculosis*: following the synthesis of cyclo(L-Tyr-L-Tyr), Cyp121 performs an oxidative C–C coupling of the two aromatic side chains to generate mycocyclusin (Fig. 24B).<sup>287</sup> Given the essential nature of CYP121 to the survival of *M. tuberculosis*,<sup>288</sup> this P450 has been extensively characterised by a number of groups, which have afforded structural, biochemical and mechanistic insights into the function of this P450.<sup>289–291</sup> Mechanistically, the formation of the C–C bond (similar to flaviolin) has been postulated to occur either by *via* proton coupled electron transfer or electron tunnelling between the two aromatic rings,<sup>177,292</sup> which is a needed to avoid having to completely re-orient the substrate within the active site during catalysis, which was an early mechanistic postulate in this case.<sup>287</sup> One of the more impressive series of transformations reported to occur during bacterial DKP synthesis is found in the biosynthesis of bicyclomycin.<sup>293,294</sup> In this pathway, the initial cyclo(L-Leu-L-Ile) DKP undergoes six oxidation events (catalysed by five  $\alpha$ -ketoglutarate/Fe<sup>2+</sup>-dependant dioxygenases (BcmB/C/E/F/G) and one cytochrome P450 (BcmD)) to afford the final, bicyclic structure of bicyclomycin. Within this pathway, the BcmD has been identified as carrying out the penultimate oxidation reaction, which affords hydroxylation of the C6 position of the DKP ring (Fig. 24C).<sup>294</sup> Thus, DKP-modification by cytochrome P450s – whilst relatively rare in bacteria – provides several examples of novel P450-catalysed transformations and such transformations should always be considered when P450s are identified in close proximity to a cyclodipeptide synthase.

**3.6.3.2 NRPS-dependent DKP biosynthesis pathways.** NRPS systems are also able to synthesise cyclic dipeptides, either as the primary function of the NRPS (such as in thaxtomin A biosynthesis) or as a shunt product produced by the spontaneous generation of a DKP from a PCP-bound dipeptide. DKP biosynthesis by NRPSs is relatively rare, with the NRPS machineries responsible for producing such DKP producing peptides containing a specific condensation domain to catalyse the formation of the DKP ring.<sup>231,295,296</sup> Whilst not a biosynthetic reaction as such, the production of DKPs *via* spontaneous cyclisation has proved to be most useful in the *in vitro* characterisation of complex NRPS machineries, as it allows the initial two






**Fig. 24** Examples of bacterial P45Os involved in tRNA-dependant DKP biosynthesis. (A) In pulcherrimin biosynthesis, following the cyclisation of two leucine residues to form the DKP P45O CypX catalyses the oxidation of both nitrogen atoms into N-oxides as well as aromatisation of the DKP ring, which leads to a compound that is able to chelate Fe ions. (B) In *M. tuberculosis*, P45O Cyp121 performs an oxidative C–C coupling of the two aromatic side chains of cyclo(Tyr–Tyr). (C) In the biosynthesis of bicyclomycin, following the cyclisation of Ile and Leu and several modifications by  $\alpha$ -ketoglutarate/Fe<sup>2+</sup>-dependant dioxygenases, the oxidation of C6 is catalysed by the P45O enzyme BcnD. P45O-catalysed reactions are shown in red, P45O enzymes are indicated in bold.

modules of an NRPS to be used as a standalone catalytic system without the requirement to reconstitute the entire NRPS.<sup>297–300</sup> Thaxtomin A, a DKP natural product produced by a two module NRPS machinery from several species of *Streptomyces*, contains two P45O enzymes within the biosynthetic cluster (TxtC and TxtE) that both represent intriguing examples of P45O-mediated transformations (Fig. 25B). TxtC has been implicated in the installation of two hydroxyl groups on the thaxtomin D precursor, with the first reaction occurring at the  $\alpha$ -carbon of

the phenylalanine residue and a subsequent aromatic hydroxylation of the aromatic ring generating thaxtomin A.<sup>231</sup> Whilst multistep transformations are somewhat common in P45Os, this example is intriguing due to the differing reactivities and positions of the two hydroxylation sites, which surely warrants further characterisation of this P45O. The second P45O, TxtE,<sup>274,301</sup> performs an even more intriguing transformation: the regiospecific 4-nitration of the indolyl moiety of L-tryptophan.<sup>274</sup> Subsequent studies have also shown that TxtE has



**Fig. 25** Examples of P45O-catalysed reactions using either free tryptophan or PCP-bound tryptophan as a substrate. In JBIR-34/-35 biosynthesis, modified tryptophan residues are incorporated. (A) In JBIR-34/-35 biosynthesis, PCP-bound tryptophan is twice hydroxylated by the P45O FmoC. (B) In thaxtomin biosynthesis, the P45O enzyme TxtE catalyses the regiospecific 4-nitration of the indolyl moiety of free tryptophan. Subsequently, the P45O TxtC installs two hydroxyl groups to finally produced thaxtomin A. P45O enzymes are indicated in bold, the P45O-catalysed reactions are shown in red. The modified Trp residues incorporated are indicated in the final compound (grey). A, adenylation domain; PCP, peptidyl carrier protein.



tolerance for certain alternate substrates.<sup>302</sup> This reaction has been shown to require NO (generated by TxtD from arginine) and O<sub>2</sub> in addition to L-Trp, with electrons provided by a competent redox partner system from NAD(P)H (*e.g.* spinach Fdx/FdR) in order to generate a ferric peroxynitrite species as the reactive intermediate.<sup>274</sup> This reaction has similarities to that performed by RufO in the nitration of tyrosine during rufomycin biosynthesis (Fig. 23A),<sup>275</sup> and demonstrates yet again the breadth of the catalytic repertoire of cytochrome P450s within secondary metabolism pathways.

## 4. Conclusions

P450 enzymes clearly play a major role in biosynthetic pathways in many bacteria. Although these P450 enzymes all belong to the same superfamily of heme-containing monooxygenases, they are able to catalyse a huge range of different reactions and in doing so provide bacteria with the access to a great variety of different secondary metabolite with altered bioactivities. The diversity of substrates of the P450s found in bacteria also serves as a testament to the impressive ability of P450s to perform diverse, challenging chemistry against a wide range of substrates and yet to do so with selectivity and specificity that is the envy of an organic chemist. The future application of such P450s as specific biocatalysts remains bright, whilst the examples discussed in this review have also demonstrated that there are undoubtedly new examples of bacterial P450 diversity still awaiting discovery within bacterial biosynthesis pathways.

## 5. Conflicts of interest

The authors declare no competing financial interest.

## 6. Acknowledgements

The authors would like to acknowledge the support of: The University of Queensland (J. J. D. V.); Monash University & EMBL Australia (M. J. C.); the Australian Research Council (DP170102220 M. J. C. and J. J. D. V.); and the National Health and Medical Research Council (APP1140619 M. J. C.). Open Access funding provided by the Max Planck Society.

## 7. References

- 1 D. R. Nelson, *Biochim. Biophys. Acta, Proteins Proteomics*, 2018, **1866**, 141–154.
- 2 D. Sirim, M. Widmann, F. Wagner and J. Pleiss, *BMC Struct. Biol.*, 2010, **10**, 34.
- 3 D. Sirim, F. Wagner, A. Lisitsa and J. Pleiss, *BMC Biochem.*, 2009, **10**, 27.
- 4 D. R. Nelson, *Hum. Genomics*, 2009, **4**, 59.
- 5 S. C. Moody and E. J. Loveridge, *J. Appl. Microbiol.*, 2014, **117**, 1549–1563.
- 6 J. D. Rudolf, C.-Y. Chang, M. Ma and B. Shen, *Nat. Prod. Rep.*, 2017, **34**, 1141–1172.
- 7 I. G. Denisov, T. M. Makris, S. G. Sligar and I. Schlichting, *Chem. Rev.*, 2005, **105**, 2253–2278.
- 8 L. Gricman, M. J. Weissenborn, S. M. Hoffmann, N. Borlinghaus, B. Hauer and J. Pleiss, *ChemistrySelect*, 2016, **1**, 1243–1251.
- 9 O. Gotoh, *J. Biol. Chem.*, 1992, **267**, 83–90.
- 10 S. Shaik, S. Cohen, Y. Wang, H. Chen, D. Kumar and W. Thiel, *Chem. Rev.*, 2010, **110**, 949–1017.
- 11 S. Shaik, D. Kumar, S. P. de Visser, A. Altun and W. Thiel, *Chem. Rev.*, 2005, **105**, 2279–2328.
- 12 F. P. Guengerich and A. W. Munro, *J. Biol. Chem.*, 2013, **288**, 17065–17073.
- 13 X. Zhang and S. Li, *Nat. Prod. Rep.*, 2017, **34**, 1061–1089.
- 14 P. R. Ortiz de Montellano and J. J. De Voss, *Nat. Prod. Rep.*, 2002, **19**, 477–493.
- 15 J. Rittle and M. T. Green, *Science*, 2010, **330**, 933–937.
- 16 M. J. Coon, A. D. N. Vaz, D. F. McGinnity and H.-M. Peng, *Contributions to Specificity in Drug Metabolism*, 1998, **26**, 1190–1193.
- 17 T. H. Yosca, J. Rittle, C. M. Krest, E. L. Onderko, A. Silakov, J. C. Calixto, R. K. Behan and M. T. Green, *Science*, 2013, **342**, 825–829.
- 18 D. C. Lamb, H. Ikeda, D. R. Nelson, J. Ishikawa, T. Skaug, C. Jackson, S. Omura, M. R. Waterman and S. L. Kelly, *Biochem. Biophys. Res. Commun.*, 2003, **307**, 610–619.
- 19 H. Ikeda, J. Ishikawa, A. Hanamoto, M. Shinose, H. Kikuchi, T. Shiba, Y. Sakaki, M. Hattori and S. Omura, *Nat. Biotechnol.*, 2003, **21**, 526.
- 20 F. Kunst, N. Ogasawara, I. Moszer, A. M. Albertini, G. Alloni, V. Azevedo, M. G. Bertero, P. Bessières, A. Bolotin, S. Borchert, R. Borriss, L. Boursier, A. Brans, M. Braun, S. C. Brignell, S. Bron, S. Brouillet, C. V. Bruschi, B. Caldwell, V. Capuano, N. M. Carter, S. K. Choi, J. J. Codani, I. F. Connerton, N. J. Cummings, R. A. Daniel, F. Denizot, K. M. Devine, A. Düsterhöft, S. D. Ehrlich, P. T. Emmerson, K. D. Entian, J. Errington, C. Fabret, E. Ferrari, D. Foulger, C. Fritz, M. Fujita, Y. Fujita, S. Fuma, A. Galizzi, N. Galleron, S. Y. Ghim, P. Glaser, A. Goffeau, E. J. Golightly, G. Grandi, G. Guiseppi, B. J. Guy, K. Haga, J. Haiech, C. R. Harwood, A. Hénaut, H. Hilbert, S. Holsappel, S. Hosono, M. F. Hullo, M. Itaya, L. Jones, B. Joris, D. Karamata, Y. Kasahara, M. Klaerr-Blanchard, C. Klein, Y. Kobayashi, P. Koetter, G. Koningstein, S. Krogh, M. Kumano, K. Kurita, A. Lapidus, S. Lardinois, J. Lauber, V. Lazarevic, S. M. Lee, A. Levine, H. Liu, S. Masuda, C. Mauël, C. Médigue, N. Medina, R. P. Mellado, M. Mizuno, D. Moestl, S. Nakai, M. Noback, D. Noone, M. O'Reilly, K. Ogawa, A. Ogiwara, B. Oudega, S. H. Park, V. Parro, T. M. Pohl, D. Portetelle, S. Porwollik, A. M. Prescott, E. Presecan, P. Pujic, B. Purnelle, G. Rapoport, M. Rey, S. Reynolds, M. Rieger, C. Rivolta, E. Rocha, B. Roche, M. Rose, Y. Sadaie, T. Sato, E. Scanlan, S. Schleich, R. Schroeter, F. Scoffone, J. Sekiguchi, A. Sekowska, S. J. Seror, P. Serror, B. S. Shin, B. Soldo, A. Sorokin, E. Tacconi, T. Takagi, H. Takahashi, K. Takemaru, M. Takeuchi, A. Tamakoshi, T. Tanaka, P. Terpstra, A. Tognoni, V. Tosato, S. Uchiyama, M. Vandenbol, F. Vannier, A. Vassarotti, A. Viari,



- R. Wambutt, E. Wedler, H. Wedler, T. Weitzenegger, P. Winters, A. Wipat, H. Yamamoto, K. Yamane, K. Yasumoto, K. Yata, K. Yoshida, H. F. Yoshikawa, E. Zumstein, H. Yoshikawa and A. Danchin, *Nature*, 1997, **390**, 249.
- 21 Y.-J. Chun, T. Shimada, R. Sanchez-Ponce, M. V. Martin, L. Lei, B. Zhao, S. L. Kelly, M. R. Waterman, D. C. Lamb and F. P. Guengerich, *J. Biol. Chem.*, 2007, **282**, 17486–17500.
- 22 R. J. Lawson, C. von Wachenfeldt, I. Haq, J. Perkins and A. W. Munro, *Biochemistry*, 2004, **43**, 12390–12409.
- 23 A. J. Green, A. W. Munro, M. R. Cheesman, G. A. Reid, C. von Wachenfeldt and S. K. Chapman, *J. Inorg. Biochem.*, 2003, **93**, 92–99.
- 24 N. Geib, T. Weber, T. Wörtz, K. Zerbe, W. Wohlleben and J. A. Robinson, *FEMS Microbiol. Lett.*, 2010, **306**, 45–53.
- 25 R. Li, N. Khaleeli and C. A. Townsend, *J. Bacteriol.*, 2000, **182**, 4087–4095.
- 26 R. M. Carman and M. T. Fletcher, *Aust. J. Chem.*, 1983, **36**, 1483–1493.
- 27 P. R. O. de Montellano and J. J. De Voss, in *Cytochrome P450 Structure Mechanism and Biochemistry*, ed. P. R. Ortiz de Montellano, Springer US, Boston, MA, 2005, pp. 183–245.
- 28 A. J. Ullah, R. I. Murray, P. K. Bhattacharyya, G. C. Wagner and I. C. Gunsalus, *J. Biol. Chem.*, 1990, **265**, 1345–1351.
- 29 J. A. Peterson, J. Y. Lu, J. Geisselsoder, S. Graham-Lorence, C. Carmona, F. Witney and M. C. Lorence, *J. Biol. Chem.*, 1992, **267**, 14193–14203.
- 30 D. B. Hawkes, *J. Biol. Chem.*, 2002, **277**, 27725–27732.
- 31 J. A. Fruetel, R. L. Mackman, J. A. Peterson and P. R. Ortiz de Montellano, *J. Biol. Chem.*, 1994, **269**, 28815–28821.
- 32 C. A. Hasemann, K. G. Ravichandran, J. A. Peterson and J. Deisenhofer, *J. Mol. Biol.*, 1994, **236**, 1169–1185.
- 33 Y. T. Mehareenna, H. Li, D. B. Hawkes, A. G. Pearson, J. De Voss and T. L. Poulos, *Biochemistry*, 2004, **43**, 9487–9494.
- 34 I. Schlichting, J. Berendzen, K. Chu, A. M. Stock, S. A. Maves, D. E. Benson, R. M. Sweet, D. Ringe, G. A. Petsko and S. G. Sligar, *Science*, 2000, **287**, 1615–1622.
- 35 F. Hannemann, A. Bichet, K. M. Ewen and R. Bernhardt, *Biochim. Biophys. Acta, Gen. Subj.*, 2007, **1770**, 330–344.
- 36 S. G. Bell, A. Dale, N. H. Rees and L.-L. Wong, *Appl. Microbiol. Biotechnol.*, 2010, **86**, 163–175.
- 37 B. Unterweger, D. M. Bulach, J. Scoble, D. J. Midgley, P. Greenfield, D. Lyras, P. Johannesen and G. J. Dumsday, *Appl. Environ. Microbiol.*, 2016, **82**, 6507–6517.
- 38 G. E. Collis, B. Unterweger, G. J. Dumsday and C. M. Forsyth, *Acta Crystallogr., Sect. E: Crystallogr. Commun.*, 2017, **73**, 1242–1245.
- 39 G. Grogan, G. A. Roberts, S. Parsons, N. J. Turner and S. L. Flitsch, *Appl. Microbiol. Biotechnol.*, 2002, **59**, 449–454.
- 40 R. W. Eaton, *J. Bacteriol.*, 1997, **179**, 3171–3180.
- 41 D. J. Smith, V. J. J. Martin and W. W. Mohn, *J. Bacteriol.*, 2004, **186**, 3631–3639.
- 42 D. J. Smith, M. A. Patrauchan, C. Florizone, L. D. Eltis and W. W. Mohn, *J. Bacteriol.*, 2008, **190**, 1575–1583.
- 43 C. A. Morgan and R. C. Wyndham, *Can. J. Microbiol.*, 2002, **48**, 49–59.
- 44 D. J. Frank, Y. Zhao, S. H. Wong, D. Basudhar, J. J. De Voss and P. R. O. de Montellano, *J. Biol. Chem.*, 2016, **291**, 7325–7333.
- 45 J. B. Johnston, H. Ouellet and P. R. Ortiz de Montellano, *J. Biol. Chem.*, 2010, **285**, 36352–36360.
- 46 Y. Aoyama, T. Horiuchi, O. Gotoh, M. Noshiro and Y. Yoshida, *J. Biochem.*, 1998, **124**, 694–696.
- 47 A. Bellamine, A. T. Mangla, W. D. Nes and M. R. Waterman, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 8937–8942.
- 48 D. C. Lamb, D. E. Kelly, N. J. Manning and S. L. Kelly, *FEBS Lett.*, 1998, **437**, 142–144.
- 49 M. P. Pietila, P. K. Vohra, B. Sanyal, N. L. Wengenack, S. Raghavakaimal and C. F. Thomas Jr, *Am. J. Respir. Cell Mol. Biol.*, 2006, **35**, 236–242.
- 50 X. Ke, G.-J. Ding, B.-X. Ma, Z.-Q. Liu, J.-F. Zhang and Y.-G. Zheng, *Process Biochem.*, 2017, **62**, 59–68.
- 51 C. J. Jackson, D. C. Lamb, T. H. Marczylo, A. G. S. Warrilow, N. J. Manning, D. J. Lowe, D. E. Kelly and S. L. Kelly, *J. Biol. Chem.*, 2002, **277**, 46959–46965.
- 52 M. Daum, H.-J. Schnell, S. Herrmann, A. Günther, R. Murillo, R. Müller, P. Bisel, M. Müller and A. Bechthold, *ChemBioChem*, 2010, **11**, 1383–1391.
- 53 C. Dürr, H.-J. Schnell, A. Luzhetskyy, R. Murillo, M. Weber, K. Welzel, A. Vente and A. Bechthold, *Chem. Biol.*, 2006, **13**, 365–377.
- 54 M. Xu, M. L. Hillwig, A. L. Lane, M. S. Tiernan, B. S. Moore and R. J. Peters, *J. Nat. Prod.*, 2014, **77**, 2144–2147.
- 55 A. Meguro, Y. Motoyoshi, K. Teramoto, S. Ueda, Y. Totsuka, Y. Ando, T. Tomita, S.-Y. Kim, T. Kimura, M. Igarashi, R. Sawa, T. Shinada, M. Nishiyama and T. Kuzuyama, *Angew. Chem.*, 2015, **127**, 4427–4430.
- 56 S.-Y. Kim, P. Zhao, M. Igarashi, R. Sawa, T. Tomita, M. Nishiyama and T. Kuzuyama, *Chem. Biol.*, 2009, **16**, 736–743.
- 57 C. Görner, P. Schrepfer, V. Redai, F. Wallrapp, B. Loll, W. Eisenreich, M. Haslbeck and T. Brück, *Microb. Cell Fact.*, 2016, **15**, 86.
- 58 F. Blasco, I. Kauffmann and R. D. Schmid, *Appl. Microbiol. Biotechnol.*, 2004, **64**, 671–674.
- 59 K. Momoi, U. Hofmann, R. D. Schmid and V. B. Urlacher, *Biochem. Biophys. Res. Commun.*, 2006, **339**, 331–336.
- 60 Z. Zhou, W. Zhang, S. Su, M. Chen, W. Lu, M. Lin, I. Molnár and Y. Xu, *Appl. Microbiol. Biotechnol.*, 2015, **99**, 10539–10546.
- 61 B. Zhao, X. Lin, L. Lei, D. C. Lamb, S. L. Kelly, M. R. Waterman and D. E. Cane, *J. Biol. Chem.*, 2008, **283**, 8183–8189.
- 62 B. Zhao, L. Lei, D. G. Vassilyev, X. Lin, D. E. Cane, S. L. Kelly, H. Yuan, D. C. Lamb and M. R. Waterman, *J. Biol. Chem.*, 2009, **284**, 36711–36719.
- 63 S. A. Agger, F. Lopez-Gallego, T. R. Hoye and C. Schmidt-Dannert, *J. Bacteriol.*, 2008, **190**, 6084–6096.
- 64 H. Harada, K. Shindo, K. Iki, A. Teraoka, S. Okamoto, F. Yu, J.-i. Hattan, R. Utsumi and N. Misawa, *Appl. Microbiol. Biotechnol.*, 2011, **90**, 467–476.
- 65 J. S. Dickschat, *Nat. Prod. Rep.*, 2016, **33**, 87–110.



- 66 Y. Yamada, T. Kuzuyama, M. Komatsu, K. Shin-Ya, S. Omura, D. E. Cane and H. Ikeda, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 857–862.
- 67 Y. Hu, W. K. W. Chou, R. Hopson and D. E. Cane, *Chem. Biol.*, 2011, **18**, 32–37.
- 68 R. Quaderer, S. Omura, H. Ikeda and D. E. Cane, *J. Am. Chem. Soc.*, 2006, **128**, 13036–13037.
- 69 D. Zhu, M.-J. Seo, H. Ikeda and D. E. Cane, *J. Am. Chem. Soc.*, 2011, **133**, 2128–2131.
- 70 L. Duan, G. Jogl and D. E. Cane, *J. Am. Chem. Soc.*, 2016, **138**, 12678–12689.
- 71 S. Takamatsu, L.-H. Xu, S. Fushinobu, H. Shoun, M. Komatsu, D. E. Cane and H. Ikeda, *J. Antibiot.*, 2011, **64**, 65–71.
- 72 R. S. Nett, M. Montanares, A. Marcassa, X. Lu, R. Nagel, T. C. Charles, P. Hedden, M. C. Rojas and R. J. Peters, *Nat. Chem. Biol.*, 2017, **13**, 69–74.
- 73 R. S. Nett, T. Contreras and R. J. Peters, *ACS Chem. Biol.*, 2017, **12**, 912–917.
- 74 M. J. Cryle, *Biochem. Soc. Trans.*, 2010, **38**, 934–939.
- 75 H. Peter and L. Michael, *Curr. Drug Metab.*, 2010, **11**, 85–104.
- 76 J. B. Johnston, P. M. Kells, L. M. Podust and P. R. Ortiz de Montellano, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 20687–20692.
- 77 X. He, M. J. Cryle, J. J. De Voss and P. R. Ortiz de Montellano, *J. Biol. Chem.*, 2005, **280**, 22697–22705.
- 78 S. Honda Malca, D. Scheps, L. Kuhnel, E. Venegas-Venegas, A. Seifert, B. M. Nestl and B. Hauer, *Chem. Commun.*, 2012, **48**, 5115–5117.
- 79 M. Bordeaux, A. Galarneau, F. Fajula and J. Drone, *Angew. Chem.*, 2011, **123**, 2123–2127.
- 80 D. Scheps, S. Honda Malca, H. Hoffmann, B. M. Nestl and B. Hauer, *Org. Biomol. Chem.*, 2011, **9**, 6727–6733.
- 81 E. G. Funhoff, U. Bauer, I. García-Rubio, B. Witholt and J. B. van Beilen, *J. Bacteriol.*, 2006, **188**, 5220–5227.
- 82 J. B. van Beilen, E. G. Funhoff, A. van Loon, A. Just, L. Kaysser, M. Bouza, R. Holtackers, M. Röthlisberger, Z. Li and B. Witholt, *Appl. Environ. Microbiol.*, 2006, **72**, 59–65.
- 83 C. J. C. Whitehouse, S. G. Bell and L.-L. Wong, *Chem. Soc. Rev.*, 2012, **41**, 1218–1260.
- 84 L. P. Wen and A. J. Fulco, *J. Biol. Chem.*, 1987, **262**, 6676–6682.
- 85 K. J. McLean, H. M. Girvan and A. W. Munro, *Expert Opin. Drug Metab. Toxicol.*, 2007, **3**, 847–863.
- 86 R. Neeli, H. M. Girvan, A. Lawrence, M. J. Warren, D. Leys, N. S. Scrutton and A. W. Munro, *FEBS Lett.*, 2005, **579**, 5582–5588.
- 87 T. Kitazume, D. C. Haines, R. W. Estabrook, B. Chen and J. A. Peterson, *Biochemistry*, 2007, **46**, 11892–11901.
- 88 H. M. Girvan, A. J. Dunford, R. Neeli, I. S. Ekanem, T. N. Waltham, M. G. Joyce, D. Leys, R. A. Curtis, P. Williams, K. Fisher, M. W. Voice and A. W. Munro, *Arch. Biochem. Biophys.*, 2011, **507**, 75–85.
- 89 S. S. Boddupalli, B. C. Pramanik, C. A. Slaughter, R. W. Estabrook and J. A. Peterson, *Arch. Biochem. Biophys.*, 1992, **292**, 20–28.
- 90 S. S. Boddupalli, R. W. Estabrook and J. A. Peterson, *J. Biol. Chem.*, 1990, **265**, 4233–4239.
- 91 M. J. Cryle and J. J. De Voss, *ChemBioChem*, 2008, **9**, 261–266.
- 92 G. Truan, M. R. Komandla, J. R. Falck and J. A. Peterson, *Arch. Biochem. Biophys.*, 1999, **366**, 192–198.
- 93 M. J. Cryle, N. J. Matovic and J. J. De Voss, *Tetrahedron Lett.*, 2007, **48**, 133–136.
- 94 M. J. Cryle and J. J. De Voss, *Tetrahedron: Asymmetry*, 2007, **18**, 547–551.
- 95 M. J. Cryle, P. Y. Hayes and J. J. De Voss, *Chem.–Eur. J.*, 2012, **18**, 15994–15999.
- 96 M. J. Cryle, P. R. Ortiz de Montellano and J. J. De Voss, *J. Org. Chem.*, 2005, **70**, 2455–2469.
- 97 M. J. Cryle, J. M. U. Stuthe, P. R. Ortiz de Montellano and J. J. De Voss, *Chem. Commun.*, 2004, 512–513, DOI: 10.1039/b315911f.
- 98 J. H. Capdevila, S. Wei, C. Helvig, J. R. Falck, Y. Belosludtsev, G. Truan, S. E. Graham-Lorence and J. A. Peterson, *J. Biol. Chem.*, 1996, **271**, 22663–22671.
- 99 M. J. Cryle and J. J. De Voss, *Angew. Chem., Int. Ed.*, 2006, **45**, 8221–8223.
- 100 M. J. Cryle, R. D. Espinoza, S. J. Smith, N. J. Matovic and J. J. De Voss, *Chem. Commun.*, 2006, 2353–2355, DOI: 10.1039/b601202g.
- 101 R. L. Wright, K. Harris, B. Solow, R. H. White and P. J. Kennelly, *FEBS Lett.*, 1996, **384**, 235–239.
- 102 M. A. McLean, S. A. Maves, K. E. Weiss, S. Krepich and S. G. Sligar, *Biochem. Biophys. Res. Commun.*, 1998, **252**, 166–172.
- 103 A. V. Puchkaev, L. S. Koo and P. R. Ortiz de Montellano, *Arch. Biochem. Biophys.*, 2003, **409**, 52–58.
- 104 A. V. Puchkaev, T. Wakagi and P. R. Ortiz de Montellano, *J. Am. Chem. Soc.*, 2002, **124**, 12682–12683.
- 105 K. S. Rabe, K. Kiko and C. M. Niemeyer, *ChemBioChem*, 2008, **9**, 420–425.
- 106 E. V. Sineva and D. R. Davydov, *Biochemistry*, 2010, **49**, 10636–10646.
- 107 D. R. Davydov, E. V. Sineva, N. Y. Davydova, D. H. Bartlett and J. R. Halpert, *Biotechnol. Appl. Biochem.*, 2013, **60**, 30–40.
- 108 I. Matsunaga, E. Kusunose, I. Yano and K. Ichihara, *Biochem. Biophys. Res. Commun.*, 1994, **201**, 1554–1560.
- 109 I. Matsunaga, N. Yokotani, O. Gotoh, E. Kusunose, M. Yamada and K. Ichihara, *J. Biol. Chem.*, 1997, **272**, 23592–23596.
- 110 I. Matsunaga, M. Yamada, E. Kusunose, Y. Nishiuchi, I. Yano and K. Ichihara, *FEBS Lett.*, 1996, **386**, 252–254.
- 111 T. Fujishiro, O. Shoji, S. Nagano, H. Sugimoto, Y. Shiro and Y. Watanabe, *J. Biol. Chem.*, 2011, **286**, 29941–29950.
- 112 D.-S. Lee, A. Yamada, H. Sugimoto, I. Matsunaga, H. Ogura, K. Ichihara, S.-i. Adachi, S.-Y. Park and Y. Shiro, *J. Biol. Chem.*, 2003, **278**, 9761–9767.
- 113 I. Matsunaga, A. Yamada, D.-S. Lee, E. Obayashi, N. Fujiwara, K. Kobayashi, H. Ogura and Y. Shiro, *Biochemistry*, 2002, **41**, 1886–1892.
- 114 M. Girhard, S. Schuster, M. Dietrich, P. Dürre and V. B. Urlacher, *Biochem. Biophys. Res. Commun.*, 2007, **362**, 114–119.



- 115 Y. Liu, C. Wang, J. Yan, W. Zhang, W. Guan, X. Lu and S. Li, *Biotechnol. Biofuels*, 2014, **7**, 28.
- 116 J. Belcher, K. J. McLean, S. Matthews, L. S. Woodward, K. Fisher, S. E. J. Rigby, D. R. Nelson, D. Potts, M. T. Baynham, D. A. Parker, D. Leys and A. W. Munro, *J. Biol. Chem.*, 2014, **289**, 6535–6550.
- 117 S. Matthews, J. D. Belcher, K. L. Tee, H. M. Girvan, K. J. McLean, S. E. J. Rigby, C. W. Levy, D. Leys, D. A. Parker, R. T. Blankley and A. W. Munro, *J. Biol. Chem.*, 2017, **292**, 5128–5143.
- 118 S. Matthews, K. L. Tee, N. J. Rattray, K. J. McLean, D. Leys, D. A. Parker, R. T. Blankley and A. W. Munro, *FEBS Lett.*, 2017, **591**, 737–750.
- 119 B. Fang, H. Xu, Y. Liu, F. Qi, W. Zhang, H. Chen, C. Wang, Y. Wang, W. Yang and S. Li, *Sci. Rep.*, 2017, **7**, 44258.
- 120 J. L. Grant, M. E. Mitchell and T. M. Makris, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 10049–10054.
- 121 J. L. Grant, C. H. Hsieh and T. M. Makris, *J. Am. Chem. Soc.*, 2015, **137**, 4940–4943.
- 122 R. J. Lawson, D. Leys, M. J. Sutcliffe, C. A. Kemp, M. R. Cheesman, S. J. Smith, J. Clarkson, W. E. Smith, I. Haq, J. B. Perkins and A. W. Munro, *Biochemistry*, 2004, **43**, 12410–12426.
- 123 J. E. Stok and J. J. De Voss, *Arch. Biochem. Biophys.*, 2000, **384**, 351–360.
- 124 J. J. De Voss and M. J. Cryle, *Met. Ions Life Sci.*, 2007, **3**, 397–435.
- 125 M. J. Cryle and J. J. De Voss, *Chem. Commun.*, 2004, 86–87, DOI: 10.1039/b311652b.
- 126 M. J. Cryle, N. J. Matovic and J. J. De Voss, *Org. Lett.*, 2003, **5**, 3341–3344.
- 127 M. J. Cryle and I. Schlichting, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 15696–15701.
- 128 M. J. Cryle, *Metallomics*, 2011, **3**, 323–326.
- 129 S. Huang, S. S. Elsayed, M. Lv, J. Tabudravu, M. E. Rateb, R. Gyampoh, K. Kyeremeh, R. Ebel, M. Jaspars, Z. Deng, Y. Yu and H. Deng, *Chem. Biol.*, 2015, **22**, 1633–1642.
- 130 S. K. P. Norah Alqahtani, E. D. James, D. M. Bis, J. A. Karty, A. L. Lane and R. Viswanathan, *Org. Biomol. Chem.*, 2015, **13**, 7177–7192.
- 131 R. Raju, A. M. Piggott, X.-C. Huang and R. J. Capon, *Org. Lett.*, 2011, **13**, 2770–2773.
- 132 W. Kitagawa, T. Ozaki, T. Nishioka, Y. Yasutake, M. Hata, M. Nishiyama, T. Kuzuyama and T. Tamura, *ChemBioChem*, 2013, **14**, 1085–1093.
- 133 Y. Yasutake, W. Kitagawa, M. Hata, T. Nishioka, T. Ozaki, M. Nishiyama, T. Kuzuyama and T. Tamura, *FEBS Lett.*, 2014, **588**, 105–110.
- 134 A. Sandmann, J. Dickschat, H. Jenke-Kodama, B. Kunze, E. Dittmann and R. Müller, *Angew. Chem., Int. Ed.*, 2007, **46**, 2712–2716.
- 135 D. Pistorius, Y. Li, A. Sandmann and R. Müller, *Mol. Biosyst.*, 2011, **7**, 3308–3315.
- 136 A. R. Howard-Jones and C. T. Walsh, *Biochemistry*, 2005, **44**, 15652–15663.
- 137 A. R. Howard-Jones and C. T. Walsh, *J. Am. Chem. Soc.*, 2007, **129**, 11016–11017.
- 138 A. R. Howard-Jones and C. T. Walsh, *J. Am. Chem. Soc.*, 2006, **128**, 12289–12298.
- 139 M. Makino, H. Sugimoto, Y. Shiro, S. Asamizu, H. Onaka and S. Nagano, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 11591–11596.
- 140 Y. Wang, H. Chen, M. Makino, Y. Shiro, S. Nagano, S. Asamizu, H. Onaka and S. Shaik, *J. Am. Chem. Soc.*, 2009, **131**, 6748–6762.
- 141 P. J. Goldman, K. S. Ryan, M. J. Hamill, A. R. Howard-Jones, C. T. Walsh, S. J. Elliott and C. L. Drennan, *Chem. Biol.*, 2012, **19**, 855–865.
- 142 K. S. Ryan, A. R. Howard-Jones, M. J. Hamill, S. J. Elliott, C. T. Walsh and C. L. Drennan, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 15311–15316.
- 143 A. P. Salas, L. Zhu, C. Sánchez, A. F. Braña, J. Rohr, C. Méndez and J. A. Salas, *Mol. Microbiol.*, 2005, **58**, 17–27.
- 144 H. Onaka, S. Asamizu, Y. Igarashi, R. Yoshida and T. Furumai, *Biosci., Biotechnol., Biochem.*, 2005, **69**, 1753–1759.
- 145 C. A. Jackson, M. B. Couger, M. Prabhakaran, K. D. Ramachandriya, P. Canaan and B. Z. Fathepure, *J. Appl. Microbiol.*, 2017, **122**, 940–952.
- 146 N. Funai, M. Funabashi, Y. Ohnishi and S. Horinouchi, *J. Bacteriol.*, 2005, **187**, 8149–8155.
- 147 B. Shen, *Curr. Opin. Chem. Biol.*, 2003, **7**, 285–295.
- 148 J. Staunton and K. J. Weissman, *Nat. Prod. Rep.*, 2001, **18**, 380–416.
- 149 R. H. Lambalot, D. E. Cane, J. J. Aparicio and L. Katz, *Biochemistry*, 1995, **34**, 1858–1866.
- 150 D. Stassi, S. Donadio, M. J. Staver and L. Katz, *J. Bacteriol.*, 1993, **175**, 182–189.
- 151 J. F. Andersen and C. R. Hutchinson, *J. Bacteriol.*, 1992, **174**, 725–735.
- 152 J. M. Weber, J. O. Leung, S. J. Swanson, K. B. Idler and J. B. McAlpine, *Science*, 1991, **252**, 114–117.
- 153 Y. Xue, D. Wilson, L. Zhao, H. Liu and D. H. Sherman, *Chem. Biol.*, 1998, **5**, 661–667.
- 154 M. V. Mendes, N. Antón, J. F. Martín and J. F. Aparicio, *Biochem. J.*, 2005, **386**, 57–62.
- 155 M. V. Mendes, E. Recio, R. Fouces, R. Luiten, J. F. Martín and J. F. Aparicio, *Cell Chem. Biol.*, 2001, **8**, 635–644.
- 156 H. Ogura, C. R. Nishida, U. R. Hoch, R. Perera, J. H. Dawson and P. R. Ortiz de Montellano, *Biochemistry*, 2004, **43**, 14712–14721.
- 157 N. Moebius, C. Ross, K. Scherlach, B. Rohm, M. Roth and C. Hertweck, *Chem. Biol.*, 2012, **19**, 1164–1174.
- 158 M. Carmody, B. Murphy, B. Byrne, P. Power, D. Rai, B. Rawlings and P. Caffrey, *J. Biol. Chem.*, 2005, **280**, 34420–34426.
- 159 S. Chen, X. Mao, Y. Shen, Y. Zhou, J. Li, L. Wang, X. Tao, L. Yang, Y. Wang, X. Zhou, Z. Deng and D. Wei, *Appl. Environ. Microbiol.*, 2009, **75**, 1778–1781.
- 160 S.-P. Liu, P.-H. Yuan, Y.-Y. Wang, X.-F. Liu, Z.-X. Zhou, Q.-t. Bu, P. Yu, H. Jiang and Y.-Q. Li, *Microbiol. Res.*, 2015, **173**, 25–33.
- 161 E. M. Seco, S. Fotso, H. Laatsch and F. Malpartida, *Chem. Biol.*, 2005, **12**, 1093–1101.



- 162 C. Olano, B. Wilkinson, C. Sánchez, S. J. Moss, R. Sheridan, V. Math, A. J. Weston, A. F. Braña, C. J. Martin, M. Oliynyk, C. Méndez, P. F. Leadlay and J. A. Salas, *Chem. Biol.*, 2004, **11**, 87–97.
- 163 M. T. Nelp and V. Bandarian, *Angew. Chem., Int. Ed.*, 2015, **54**, 10627–10629.
- 164 C. J. Schulze, W. M. Bray, F. Loganzo, M.-H. Lam, T. Szal, A. Villalobos, F. E. Koehn and R. G. Linington, *J. Nat. Prod.*, 2014, **77**, 2570–2574.
- 165 J. Li, X. Tang, T. Awakawa and B. S. Moore, *Angew. Chem., Int. Ed.*, 2017, **56**, 12234–12239.
- 166 M. L. Dickens and W. R. Strohl, *J. Bacteriol.*, 1996, **178**, 3389–3395.
- 167 M. L. Dickens, N. D. Priestley and W. R. Strohl, *J. Bacteriol.*, 1997, **179**, 2641–2650.
- 168 R. J. Walczak, M. L. Dickens, N. D. Priestley and W. R. Strohl, *J. Bacteriol.*, 1999, **181**, 298–304.
- 169 F. Kudo, K. Kawamura, T. Furuya, H. Yamanishi, A. Motegi, A. Komatsubara, M. Numakura, A. Miyanaga and T. Eguchi, *ChemBioChem*, 2016, **17**, 233–238.
- 170 Y. Anzai, S. Li, M. R. Chaulagain, K. Kinoshita, F. Kato, J. Montgomery and D. H. Sherman, *Chem. Biol.*, 2008, **15**, 950–959.
- 171 J. C. Carlson, S. Li, S. S. Gunatilleke, Y. Anzai, D. A. Burr, L. M. Podust and D. H. Sherman, *Nat. Chem.*, 2011, **3**, 628–633.
- 172 R. A. Butcher, F. C. Schroeder, M. A. Fischbach, P. D. Straight, R. Kolter, C. T. Walsh and J. Clardy, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 1506–1509.
- 173 J. J. Reddick, S. A. Antolak and G. M. Raner, *Biochem. Biophys. Res. Commun.*, 2007, **358**, 363–367.
- 174 S. H. Wong, S. G. Bell and J. J. De Voss, *Pure Appl. Chem.*, 2017, **89**, 841–852.
- 175 B. Zhao, F. P. Guengerich, A. Bellamine, D. C. Lamb, M. Izumikawa, L. Lei, L. M. Podust, M. Sundaramoorthy, J. A. Kalaitzis, L. M. Reddy, S. L. Kelly, B. S. Moore, D. Stec, M. Voehler, J. R. Falck, T. Shimada and M. R. Waterman, *J. Biol. Chem.*, 2005, **280**, 11599–11607.
- 176 B. Zhao, D. C. Lamb, L. Lei, S. L. Kelly, H. Yuan, D. L. Hachey and M. R. Waterman, *Biochemistry*, 2007, **46**, 8725–8733.
- 177 K. Dornevil, I. Davis, A. J. Fielding, J. R. Terrell, L. Ma and A. Liu, *J. Biol. Chem.*, 2017, **292**, 13645–13657.
- 178 M. E. A. Richter, N. Traitcheva, U. Knüpfer and C. Hertweck, *Angew. Chem., Int. Ed.*, 2008, **47**, 8872–8875.
- 179 J. He, M. Müller and C. Hertweck, *J. Am. Chem. Soc.*, 2004, **126**, 16742–16743.
- 180 H. Ikeda, T. Nonomiya, M. Usami, T. Ohta and S. Ōmura, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 9509–9514.
- 181 M. J. Smanski, R. M. Peterson and B. Shen, in *Methods in Enzymology*, ed. D. A. Hopwood, Academic Press, 2012, vol. 515, pp. 163–186.
- 182 G. Zoicher, M. E. A. Richter, U. Mueller and C. Hertweck, *J. Am. Chem. Soc.*, 2011, **133**, 2292–2302.
- 183 M. Richter, B. Busch, K. Ishida, B. S. Moore and C. Hertweck, *ChemBioChem*, 2012, **13**, 2196–2199.
- 184 Y. Xie, B. Wang, J. Liu, J. Zhou, J. Ma, H. Huang and J. Ju, *ChemBioChem*, 2012, **13**, 2745–2757.
- 185 Y. Xie, Q. Li, Y. Song, J. Ma and J. Ju, *ChemBioChem*, 2014, **15**, 1183–1189.
- 186 Q. Li, Y. Chen, G. Zhang and H. Zhang, *FEBS Lett.*, 2017, **591**, 1295–1304.
- 187 M. E. Yurkovich, R. Jenkins, Y. Sun, M. Tosin and P. F. Leadlay, *Chem. Commun.*, 2017, **53**, 2182–2185.
- 188 X. Tang, J. Li and B. S. Moore, *ChemBioChem*, 2017, **18**, 1072–1076.
- 189 W. Tao, M. E. Yurkovich, S. Wen, K. E. Lebe, M. Samborsky, Y. Liu, A. Yang, Y. Liu, Y. Ju, Z. Deng, M. Tosin, Y. Sun and P. F. Leadlay, *Chem. Sci.*, 2016, **7**, 376–385.
- 190 J. Havemann, M. E. Yurkovich, R. Jenkins, S. Harringer, W. Tao, S. Wen, Y. Sun, P. F. Leadlay and M. Tosin, *Chem. Commun.*, 2017, **53**, 1912–1915.
- 191 J. G. McCoy, H. D. Johnson, S. Singh, C. A. Bingman, I.-K. Lei, J. S. Thorson and G. N. Phillips, *Proteins: Struct., Funct., Bioinf.*, 2009, **74**, 50–60.
- 192 Q. Zhao, Q. He, W. Ding, M. Tang, Q. Kang, Y. Yu, W. Deng, Q. Zhang, J. Fang, G. Tang and W. Liu, *Chem. Biol.*, 2008, **15**, 693–705.
- 193 W. Ding, W. Deng, M. Tang, Q. Zhang, G. Tang, Y. Bi and W. Liu, *Mol. Biosyst.*, 2010, **6**, 1071–1081.
- 194 L. Song, L. Laureti, C. Corre, P. Leblond, B. Aigle and G. L. Challis, *J. Antibiot.*, 2014, **67**, 71–76.
- 195 L. Laureti, L. Song, S. Huang, C. Corre, P. Leblond, G. L. Challis and B. Aigle, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 6258–6263.
- 196 D. M. Bis, Y. H. Ban, E. D. James, N. Alqahtani, R. Viswanathan and A. L. Lane, *ChemBioChem*, 2015, **16**, 990–997.
- 197 B. Frank, S. C. Wenzel, H. B. Bode, M. Scharfe, H. Blöcker and R. Müller, *J. Mol. Biol.*, 2007, **374**, 24–38.
- 198 S. A. Borisova, L. Zhao, C. E. Melançon, C.-L. Kao and H.-w. Liu, *J. Am. Chem. Soc.*, 2004, **126**, 6534–6535.
- 199 M. C. Moncrieffe, M.-J. Fernandez, D. Spiteller, H. Matsumura, N. J. Gay, B. F. Luisi and P. F. Leadlay, *J. Mol. Biol.*, 2012, **415**, 92–101.
- 200 P. G. Arnison, M. J. Bibb, G. Bierbaum, A. A. Bowers, T. S. Bugni, G. Bulaj, J. A. Camarero, D. J. Campopiano, G. L. Challis, J. Clardy, P. D. Cotter, D. J. Craik, M. Dawson, E. Dittmann, S. Donadio, P. C. Dorrestein, K.-D. Entian, M. A. Fischbach, J. S. Garavelli, U. Goransson, C. W. Gruber, D. H. Haft, T. K. Hemscheidt, C. Hertweck, C. Hill, A. R. Horswill, M. Jaspars, W. L. Kelly, J. P. Klinman, O. P. Kuipers, A. J. Link, W. Liu, M. A. Marahiel, D. A. Mitchell, G. N. Moll, B. S. Moore, R. Muller, S. K. Nair, I. F. Nes, G. E. Norris, B. M. Olivera, H. Onaka, M. L. Patchett, J. Piel, M. J. T. Reaney, S. Rebuffat, R. P. Ross, H.-G. Sahl, E. W. Schmidt, M. E. Selsted, K. Severinov, B. Shen, K. Sivonen, L. Smith, T. Stein, R. D. Sussmuth, J. R. Tagg, G.-L. Tang, A. W. Truman, J. C. Vederas, C. T. Walsh, J. D. Walton, S. C. Wenzel, J. M. Willey and W. A. van der Donk, *Nat. Prod. Rep.*, 2013, **30**, 108–160.
- 201 Q. Zheng, H. Fang and W. Liu, *Org. Biomol. Chem.*, 2017, **15**, 3376–3390.



- 202 L. M. Repka, J. R. Chekan, S. K. Nair and W. A. van der Donk, *Chem. Rev.*, 2017, **117**, 5457–5520.
- 203 L. C. Foulston and M. J. Bibb, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 13461–13466.
- 204 Z. Zhang, G. A. Hudson, N. Mahanta, J. I. Tietz, W. A. van der Donk and D. A. Mitchell, *J. Am. Chem. Soc.*, 2016, **138**, 15511–15514.
- 205 G. A. Hudson, Z. Zhang, J. I. Tietz, D. A. Mitchell and W. A. van der Donk, *J. Am. Chem. Soc.*, 2015, **137**, 16012–16015.
- 206 T. S. Young and C. T. Walsh, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 13053–13058.
- 207 Q. Zheng, S. Wang, R. Liao and W. Liu, *ACS Chem. Biol.*, 2016, **11**, 2673–2678.
- 208 W. J. K. Crone, N. M. Vior, J. Santos-Aberturas, L. G. Schmitz, F. J. Leeper and A. W. Truman, *Angew. Chem., Int. Ed.*, 2016, **55**, 9639–9643.
- 209 W. J. K. Crone, F. J. Leeper and A. W. Truman, *Chem. Sci.*, 2012, **3**, 3516–3521.
- 210 J. P. Gomez-Escribano, L. Song, M. J. Bibb and G. L. Challis, *Chem. Sci.*, 2012, **3**, 3522–3525.
- 211 L. Huo, S. Rachid, M. Stadler, S. C. Wenzel and R. Müller, *Chem. Biol.*, 2012, **19**, 1278–1287.
- 212 J. G. Gober, S. V. Ghodge, J. W. Bogart, W. J. Wever, R. R. Watkins, E. M. Brustad and A. A. Bowers, *ACS Chem. Biol.*, 2017, **12**, 1726–1731.
- 213 J. A. E. Payne, M. Schoppet, M. H. Hansen and M. J. Cryle, *Mol. Biosyst.*, 2017, **13**, 9–22.
- 214 G. H. Hur, C. R. Vickery and M. D. Burkart, *Nat. Prod. Rep.*, 2012, **29**, 1074–1098.
- 215 C. T. Walsh, R. V. O'Brien and C. Khosla, *Angew. Chem., Int. Ed.*, 2013, **52**, 7098–7124.
- 216 O. Puk, D. Bischoff, C. Kittel, S. Pelzer, S. Weist, E. Stegmann, R. D. Süssmuth and W. Wohlleben, *J. Bacteriol.*, 2004, **186**, 6093–6100.
- 217 J. Recktenwald, R. Shawky, O. Puk, F. Pfennig, U. Keller, W. Wohlleben and S. Pelzer, *Microbiology*, 2002, **148**, 1105–1118.
- 218 O. Puk, P. Huber, D. Bischoff, J. Recktenwald, G. Jung, R. D. Süssmuth, K.-H. van Pee, W. Wohlleben and S. Pelzer, *Chem. Biol.*, 2002, **9**, 225–235.
- 219 M. J. Cryle, A. Meinhart and I. Schlichting, *J. Biol. Chem.*, 2010, **285**, 24562–24574.
- 220 H. Chen and C. T. Walsh, *Chem. Biol.*, 2001, **8**, 301–312.
- 221 Y. Hirose, K. Watanabe, A. Minami, T. Nakamura, H. Oguri and H. Oikawa, *J. Antibiot.*, 2011, **64**, 117–122.
- 222 C. Zhang, L. Kong, Q. Liu, X. Lei, T. Zhu, J. Yin, B. Lin, Z. Deng and D. You, *PLoS One*, 2013, **8**, e56772.
- 223 K. Koketsu, H. Oguri, K. Watanabe and H. Oikawa, *Org. Lett.*, 2006, **8**, 4719–4722.
- 224 U. Galm, E. Wendt-Pienkowski, L. Wang, N. P. George, T.-J. Oh, F. Yi, M. Tao, J. M. Coughlin and B. Shen, *Mol. Biosyst.*, 2009, **5**, 77–90.
- 225 H. Chen, B. K. Hubbard, S. E. O'Connor and C. T. Walsh, *Chem. Biol.*, 2002, **9**, 103–112.
- 226 C. E. Wise and T. M. Makris, *ACS Chem. Biol.*, 2017, **12**, 1316–1326.
- 227 S. Mulyani, E. Egel, C. Kittel, S. Turkanovic, W. Wohlleben, R. D. Süssmuth and K.-H. van Pee, *ChemBioChem*, 2010, **11**, 266–271.
- 228 M. Pacholec, N. J. Hillson and C. T. Walsh, *Biochemistry*, 2005, **44**, 12819–12826.
- 229 A. V. Ramaswamy, C. M. Sorrels and W. H. Gerwick, *J. Nat. Prod.*, 2007, **70**, 1977–1986.
- 230 A. Muliandi, Y. Katsuyama, K. Sone, M. Izumikawa, T. Moriya, J. Hashimoto, I. Kozono, M. Takagi, K. Shin-ya and Y. Ohnishi, *Chem. Biol.*, 2014, **21**, 923–934.
- 231 F. G. Healy, S. B. Krasnoff, M. Wach, D. M. Gibson and R. Loria, *J. Bacteriol.*, 2002, **184**, 2019–2029.
- 232 S. Pohle, C. Appelt, M. Roux, H.-P. Fiedler and R. D. Süssmuth, *J. Am. Chem. Soc.*, 2011, **133**, 6194–6205.
- 233 V. Schubert, F. Di Meo, P.-L. Saaidi, S. Bartoschek, H.-P. Fiedler, P. Trouillas and R. D. Süssmuth, *Chem.–Eur. J.*, 2014, **20**, 4948–4955.
- 234 S. Uhlmann, R. D. Süssmuth and M. J. Cryle, *ACS Chem. Biol.*, 2013, **8**, 2586–2596.
- 235 K. Haslinger, C. Brieke, S. Uhlmann, L. Sieverling, R. D. Süssmuth and M. J. Cryle, *Angew. Chem., Int. Ed.*, 2014, **53**, 8518–8522.
- 236 B. Kokona, E. S. Winesett, A. Nikolai von Krusenstiern, M. J. Cryle, R. Fairman and L. K. Charkoudian, *Anal. Biochem.*, 2016, **495**, 42–51.
- 237 C. Fu, L. Keller, A. Bauer, M. Brönstrup, A. Froidbise, P. Hammann, J. Herrmann, G. Mondesert, M. Kurz, M. Schiell, D. Schummer, L. Toti, J. Wink and R. Müller, *J. Am. Chem. Soc.*, 2015, **137**, 7692–7705.
- 238 X. Wang, J. Tabudravu, M. E. Rateb, K. J. Annand, Z. Qin, M. Jaspars, Z. Deng, Y. Yu and H. Deng, *Mol. Biosyst.*, 2013, **9**, 1286–1289.
- 239 D. Zabala, J. W. Cartwright, D. M. Roberts, B. J. C. Law, L. Song, M. Samborsky, P. F. Leadlay, J. Micklefield and G. L. Challis, *J. Am. Chem. Soc.*, 2016, **138**, 4342–4345.
- 240 G. Yim, M. N. Thaker, K. Koteva and G. Wright, *J. Antibiot.*, 2014, **67**, 31–41.
- 241 E. Stegmann, H.-J. Frasch and W. Wohlleben, *Curr. Opin. Microbiol.*, 2010, **13**, 595–602.
- 242 R. S. Al Toma, C. Brieke, M. J. Cryle and R. D. Süssmuth, *Nat. Prod. Rep.*, 2015, **32**, 1207–1235.
- 243 M. Peschke, M. Gonsior, R. D. Süssmuth and M. J. Cryle, *Curr. Opin. Struct. Biol.*, 2016, **41**, 46–53.
- 244 B. Hadatsch, D. Butz, T. Schmiederer, J. Studle, W. Wohlleben, R. Süssmuth and E. Stegmann, *Chem. Biol.*, 2007, **14**, 1078–1089.
- 245 D. Bischoff, B. Bister, M. Bertazzo, V. Pfeifer, E. Stegmann, G. J. Nicholson, S. Keller, S. Pelzer, W. Wohlleben and R. D. Süssmuth, *ChemBioChem*, 2005, **6**, 267–272.
- 246 D. Bischoff, S. Pelzer, A. Holtzel, G. J. Nicholson, S. Stockert, W. Wohlleben, G. Jung and R. D. Süssmuth, *Angew. Chem., Int. Ed.*, 2001, **40**, 1693–1696.
- 247 D. Bischoff, S. Pelzer, B. Bister, G. J. Nicholson, S. Stockert, M. Schirle, W. Wohlleben, G. Jung and R. D. Süssmuth, *Angew. Chem., Int. Ed.*, 2001, **40**, 4688–4691.



- 248 R. D. Sussmuth, S. Pelzer, G. Nicholson, T. Walk, W. Wohlleben and G. Jung, *Angew. Chem., Int. Ed.*, 1999, **38**, 1976–1979.
- 249 E. Stegmann, S. Pelzer, D. Bischoff, O. Puk, S. Stockert, D. Butz, K. Zerbe, J. Robinson, R. D. Sussmuth and W. Wohlleben, *J. Biotechnol.*, 2006, **124**, 640–653.
- 250 P. C. Schmartz, K. Wolfel, K. Zerbe, E. Gad, E. El Tamany, H. K. Ibrahim, K. Abou-Hadeed and J. A. Robinson, *Angew. Chem., Int. Ed.*, 2012, **51**, 11468–11472.
- 251 K. Woithe, N. Geib, K. Zerbe, D. B. Li, M. Heck, S. Fournier-Rousset, O. Meyer, F. Vitali, N. Matoba, K. Abou-Hadeed and J. A. Robinson, *J. Am. Chem. Soc.*, 2007, **129**, 6887–6895.
- 252 K. Zerbe, K. Woithe, D. B. Li, F. Vitali, L. Bigler and J. A. Robinson, *Angew. Chem., Int. Ed.*, 2004, **43**, 6709–6713.
- 253 K. Haslinger, C. Redfield and M. J. Cryle, *Proteins: Struct., Funct., Bioinf.*, 2015, **83**, 711–721.
- 254 M. Peschke, K. Haslinger, C. Brieke, J. Reinstein and M. Cryle, *J. Am. Chem. Soc.*, 2016, **138**, 6746–6753.
- 255 K. Haslinger, M. Peschke, C. Brieke, E. Maximowitsch and M. J. Cryle, *Nature*, 2015, **521**, 105–109.
- 256 C. Brieke, M. Peschke, K. Haslinger and M. J. Cryle, *Angew. Chem., Int. Ed.*, 2015, **54**, 15715–15719.
- 257 J. Tailhades, M. Schoppet, A. Greule, M. Peschke, C. Brieke and M. J. Cryle, *Chem. Commun.*, 2018, **54**(17), 2146–2149.
- 258 M. Peschke, C. Brieke, R. J. A. Goode, R. B. Schittenhelm and M. J. Cryle, *Biochemistry*, 2017, **56**, 1239–1247.
- 259 V. Ulrich, M. Peschke, C. Brieke and M. Cryle, *Mol. Biosyst.*, 2016, **12**, 2992–3004.
- 260 V. Ulrich, C. Brieke and M. Cryle, *Beilstein J. Org. Chem.*, 2016, **12**, 2849–2864.
- 261 M. Peschke, C. Brieke and M. J. Cryle, *Sci. Rep.*, 2016, **6**, 35584.
- 262 C. Brieke, V. Kratzig, K. Haslinger, A. Winkler and M. J. Cryle, *Org. Biomol. Chem.*, 2015, **13**, 2012–2021.
- 263 K. Haslinger, E. Maximowitsch, C. Brieke, A. Koch and M. J. Cryle, *ChemBioChem*, 2014, **15**, 2719–2728.
- 264 H.-T. Chiu, B. K. Hubbard, A. N. Shah, J. Eide, R. A. Fredenburg, C. T. Walsh and C. Khosla, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 8548–8553.
- 265 B. Nazari, C. C. Forneris, M. I. Gibson, K. Moon, K. R. Schramma and M. R. Seyedsayamdost, *MedChemComm*, 2017, **8**, 780–788.
- 266 O.-K. Park, H.-Y. Choi, G.-W. Kim and W.-G. Kim, *ChemBioChem*, 2016, **17**, 1725–1731.
- 267 A. Mollo, A. N. von Krusenstiern, J. A. Bulos, V. Ulrich, K. S. Akerfeldt, M. J. Cryle and L. K. Charkoudian, *RSC Adv.*, 2017, **7**, 35376–35384.
- 268 W.-T. Liu, R. D. Kersten, Y.-L. Yang, B. S. Moore and P. C. Dorrestein, *J. Am. Chem. Soc.*, 2011, **133**, 18010–18013.
- 269 X. Jin, M. Rao, W. Wei, M. Ge, J. Liu, D. Chen and Y. Liang, *Biotechnol. Lett.*, 2012, **34**, 2283–2289.
- 270 J. Ma, Z. Wang, H. Huang, M. Luo, D. Zuo, B. Wang, A. Sun, Y.-Q. Cheng, C. Zhang and J. Ju, *Angew. Chem., Int. Ed.*, 2011, **50**, 7797–7802.
- 271 H. Zhang, J. Chen, H. Wang, Y. Xie, J. Ju, Y. Yan and H. Zhang, *FEBS Lett.*, 2013, **587**, 1675–1680.
- 272 M. Schorn, J. Zettler, J. P. Noel, P. C. Dorrestein, B. S. Moore and L. Kaysser, *ACS Chem. Biol.*, 2014, **9**, 301–309.
- 273 S. Zhang, J. Zhu, D. L. Zechel, C. Jessen-Trefzer, R. T. Eastman, T. Paululat and A. Bechthold, *ChemBioChem*, 2018, **19**, 272–279.
- 274 S. M. Barry, J. A. Kers, E. G. Johnson, L. Song, P. R. Aston, B. Patel, S. B. Krasnoff, B. R. Crane, D. M. Gibson, R. Loria and G. L. Challis, *Nat. Chem. Biol.*, 2012, **8**, 814–816.
- 275 H. Tomita, Y. Katsuyama, H. Minami and Y. Ohnishi, *J. Biol. Chem.*, 2017, **292**, 15859–15869.
- 276 M. Gunsior, S. D. Breazeale, A. J. Lind, J. Ravel, J. W. Janc and C. A. Townsend, *Chem. Biol.*, 2004, **11**, 927–938.
- 277 N. M. Gaudelli, D. H. Long and C. A. Townsend, *Nature*, 2015, **520**, 383–387.
- 278 N. M. Gaudelli and C. A. Townsend, *Nat. Chem. Biol.*, 2014, **10**, 251–258.
- 279 A. M. Reeve, S. D. Breazeale and C. A. Townsend, *J. Biol. Chem.*, 1998, **273**, 30695–30703.
- 280 W. L. Kelly and C. A. Townsend, *J. Am. Chem. Soc.*, 2002, **124**, 8186–8187.
- 281 M. Sørensen, E. H. J. Neilson and B. L. Møller, *Mol. Plant*, 2018, **11**, 95–117.
- 282 L. Ray, K. Yamanaka and B. S. Moore, *Angew. Chem., Int. Ed.*, 2015, **55**, 364–367.
- 283 D. J. Edwards and W. H. Gerwick, *J. Am. Chem. Soc.*, 2004, **126**, 11432–11433.
- 284 M. U. Huynh, M. C. Elston, N. M. Hernandez, D. B. Ball, S.-i. Kajiyama, K. Irie, W. H. Gerwick and D. J. Edwards, *J. Nat. Prod.*, 2010, **73**, 71–74.
- 285 M. Moutiez, P. Belin and M. Gondry, *Chem. Rev.*, 2017, **117**, 5578–5618.
- 286 M. J. Cryle, S. G. Bell and I. Schlichting, *Biochemistry*, 2010, **49**, 7282–7296.
- 287 P. Belin, M. H. Le Du, A. Fielding, O. Lequin, M. Jacquet, J.-B. Charbonnier, A. Lecoq, R. Thai, M. Courçon, C. Masson, C. Dugave, R. Genet, J.-L. Pernodet and M. Gondry, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 7426–7431.
- 288 K. J. McLean, P. Carroll, D. G. Lewis, A. J. Dunford, H. E. Seward, R. Neeli, M. R. Cheesman, L. Marsollier, P. Douglas, W. E. Smith, I. Rosenkrands, S. T. Cole, D. Leys, T. Parish and A. W. Munro, *J. Biol. Chem.*, 2008, **283**, 33406–33416.
- 289 M. Fonvielle, M.-H. Le Du, O. Lequin, A. Lecoq, M. Jacquet, R. Thai, S. Dubois, G. Grach, M. Gondry and P. Belin, *J. Biol. Chem.*, 2013, **288**, 17347–17359.
- 290 H. E. Seward, A. Roujeinikova, K. J. McLean, A. W. Munro and D. Leys, *J. Biol. Chem.*, 2006, **281**, 39437–39443.
- 291 D. Leys, C. G. Mowat, K. J. McLean, A. Richmond, S. K. Chapman, M. D. Walkinshaw and A. W. Munro, *J. Biol. Chem.*, 2003, **278**, 5141–5147.
- 292 V. G. Dumas, L. A. Defelipe, A. A. Petruk, A. G. Turjanski and M. A. Marti, *Proteins: Struct., Funct., Bioinf.*, 2014, **82**, 1004–1021.
- 293 J. B. Patteson, W. Cai, R. A. Johnson, K. C. Santa Maria and B. Li, *Biochemistry*, 2018, **57**(1), 61–65.
- 294 S. Meng, W. Han, J. Zhao, X.-H. Jian, H.-X. Pan and G.-L. Tang, *Angew. Chem., Int. Ed.*, 2018, **57**, 719–723.
- 295 F. G. Healy, M. Wach, S. B. Krasnoff, D. M. Gibson and R. Loria, *Mol. Microbiol.*, 2000, **38**, 794–804.



- 296 B. Gu, S. He, X. Yan and L. Zhang, *Appl. Microbiol. Biotechnol.*, 2013, **97**, 8439–8453.
- 297 H. Kries, D. L. Niquille and D. Hilvert, *Chem. Biol.*, 2015, **22**, 640–648.
- 298 H. Kries, R. Wachtel, A. Pabst, B. Wanner, D. Niquille and D. Hilvert, *Angew. Chem., Int. Ed.*, 2014, **53**, 10105–10108.
- 299 T. Stachelhaus, H. D. Mootz, V. Bergendahl and M. A. Marahiel, *J. Biol. Chem.*, 1998, **273**, 22773–22781.
- 300 P. J. Belshaw, C. T. Walsh and T. Stachelhaus, *Science*, 1999, **284**, 486–489.
- 301 F. Yu, M. Li, C. Xu, Z. Wang, H. Zhou, M. Yang, Y. Chen, L. Tang and J. He, *PLoS One*, 2013, **8**, e81526.
- 302 S. C. Dodani, J. K. B. Cahn, T. Heinisch, S. Brinkmann-Chen, J. A. McIntosh and F. H. Arnold, *ChemBioChem*, 2014, **15**, 2259–2267.

